[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Merits Holdings Co. dba Merits Health Products, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":182},{"warningLetters":4,"total":181},[5,30,54,76,97,121,140,161],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":29,"medical_device_id":19,"response_letter_date":19},894,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-05-20T04:00:00Z\">05\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-24T04:00:00Z\">03\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funited-health-products-inc-697777-03242025\">United Health Products, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","Bioresearch Monitoring Program\u002FInstitutional Review Board (IRB)","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics\u003Cbr>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brian Thom\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>United Health Products, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>520 Fellowship Road, Suite #D-406\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mt. Laurel\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08054\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@uhpcorp.com\"> (b)(6)@uhpcorp.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 24, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Thom:\u003C\u002Fp>\u003Cp>This Warning Letter is to inform you of objectionable conditions observed during the Food and Drug Administration (FDA) inspection conducted at United Health Products, Inc. from September 23, 2024, to October 4, 2024, by an investigator from the FDA’s Office of Bioresearch Monitoring Inspectorate (OBMI). This inspection was conducted to determine whether activities and procedures as sponsor in the significant risk clinical study “Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting,” for CelluSTAT Absorbable HemoStat, Premarket Approval (PMA) Application, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, complied with applicable federal regulations. The CelluSTAT Absorbable Hemostat is a device as that term is defined in section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h)(1), because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. This letter also requests prompt corrective action to address the violations cited and discusses your written response, dated October 25, 2024, to the noted violations.\u003C\u002Fp>\u003Cp>The inspection was conducted under the Bioresearch Monitoring (BIMO) Program designed to ensure that data and information contained in requests for Investigational Device Exemptions (IDEs), PMA applications, and Premarket Notification submissions are scientifically valid and accurate. Another objective of the program is to ensure that human subjects are protected from undue hazard or risk during the course of scientific investigations.\u003C\u002Fp>\u003Cp>Our review of the inspection report prepared by OBMI revealed serious violations of Title 21, Code of Federal Regulations (CFR) Part 812 - Investigational Device Exemptions and 21 CFR Part 50 - Protection of Human Subjects, which concern requirements prescribed under section 520(g) of the Act, 21 U.S.C. § 360j(g). At the close of the inspection, the FDA investigator presented an inspectional observations Form FDA-483 for your review and discussed the observations listed on the form with you. The deviations noted on Form FDA-483, your written response, and our subsequent review of the inspection report are discussed below:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to submit an IDE application to FDA and failure to obtain FDA approval prior to beginning an investigation for which FDA’s approval is required [21 CFR 812.20(a)(1) and (2).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Sponsors must submit an IDE application to the FDA if the sponsor intends to use a significant risk device in a clinical investigation. In addition, a sponsor may not begin an investigation for which FDA’s approval of an application is required until FDA has approved the application. You did not submit an IDE application to FDA or obtain FDA approval prior to beginning such an investigation.\u003C\u002Fp>\u003Cp>You conducted your study, UHP001, without submission and approval of an IDE application to FDA. The Western Copernicus Group (WCG) Institutional Review Board (IRB) determined that the procedures in the research posed a potential significant risk to subjects and requested documentation of the FDA’s non-significant risk (NSR) determination in multiple communications. You provided to the IRB FDA written feedback for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and FDA meeting minutes for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which had been modified from the FDA official correspondence by removal of references to future IDE submission and by addition of language that purported to indicate FDA agreement that the study was non-significant risk (NSR). In particular, you provided the transmittal email from FDA along with these meeting minutes, which imply that the meeting minutes that you submitted to the IRB were those provided by FDA to you as the official record. The IRB used this documentation, which misrepresented the FDA risk determination for this study, to support their determination of the regulatory status of the study, and to review and approve this study without FDA oversight.\u003C\u002Fp>\u003Cp>FDA maintains that the study UHP0001 that you have conducted to support \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a Class III device is considered a significant risk device clinical investigation for which you should have submitted an IDE application to FDA and obtained FDA approval prior to initiation. Your device is an absorbable hemostat intended to be used as an adjunct to primary hemostasis in surgical procedures to assist in controlling capillary, venous and small arterial hemorrhage when other conventional methods are ineffective or impractical. Absorbable hemostatic agents are intended to be absorbed into the body and are Class III devices per 21 CFR 878.4490. The agency considers such devices to be significant risk devices because they are absorbed internally and present “a potential for serious risk to the health, safety, or welfare of a subject” per 21 CFR 812.3(m). 21 CFR 812.20(a) requires any sponsor who intends to use a significant risk device in an investigation to submit an application to FDA, and to wait to begin the investigation until FDA has approved the application. FDA approval of an IDE application helps to ensure subject safety and that the risks associated with the device and study procedures are minimized.\u003C\u002Fp>\u003Cp>This was conveyed to you in the Form FDA-483, and your response dated October 25, 2024 is inadequate. Your written response includes a discussion of the interactions with FDA regarding this study and describes your misunderstanding of those interactions and of NSR\u002Fsignificant risk studies. It indicates that the meeting minutes for \u003Cstrong>(b)(4)\u003C\u002Fstrong> that you had provided to the IRB were your modifications to the minutes received from FDA and that you had informally emailed them to FDA. However, there is no record of your submission of these revised meeting minutes to FDA either by email or with a Meeting Minutes Disagreement amendment, the procedure outlined in FDA’s transmittal email for handling changes to meeting minutes. Importantly, there is also no agreement by FDA on these meeting minutes that you had revised. Your response also does not speak to the modifications that were made to the official FDA correspondence for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, where you inserted the word “NSR” in describing the name of the study and removed references to a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. FDA is greatly concerned about your misrepresentation of the FDA’s stance regarding the risk determination of the study to the IRB, which resulted in you inappropriately conducting this study without submitting and obtaining approval of an IDE application from FDA prior to initiation.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to ensure proper monitoring of the investigation [21 CFR 812.40].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Sponsors are responsible for ensuring that a clinical investigation is properly monitored. However, you failed to properly monitor your clinical investigation. Examples include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>a. Although you had described in the study protocol, UHP001, sections 10 and 14.9, that details regarding monitoring would be provided in the study specific Monitoring Plan and clinical site monitoring would be documented in a Clinical Monitoring Plan (CMP), respectively, you did not have an effective and implemented CMP during study conduct.\u003C\u002Fp>\u003Cp>b. You did not maintain adequate documentation regarding those monitoring activities that did occur:\u003C\u002Fp>\u003Cp>i. You failed to maintain adequate site initiation visit (SIV) documentation for the two clinical investigation sites. There were several discrepancies in documentation of SIV Monitoring Visit Reports, investigator site’s personnel training logs (SIV Training Logs), and Site Visit Logs. For example, the SIV Monitoring Visit Report for site 01 documented the visit was held on-site on December 17, 2018, with the clinical investigator and research coordinator. However, the SIV Training Log for site 01 documented the clinical investigator received SIV training on December 10, 2018, and the research coordinator received SIV training on March 19, 2019. The Site Visit Log for site 01 documented a single SIV date as December 19, 2018.\u003C\u002Fp>\u003Cp>ii. You failed to maintain adequate interim monitoring documentation for the two clinical investigation sites. For example, the Site Visit Log for site 01 documented the interim monitoring visit was held on-site on July 9, 2019, but there was no interim monitoring report for this visit. In addition, the site visit log for site 02 documented the interim monitoring visit was held on-site on September 10, 2019, but there was no interim monitoring report for this visit.\u003C\u002Fp>\u003Cp>Proper monitoring helps ensure that the safety, rights, and well-being of the subjects are protected, and that the data are complete and accurate. Monitoring should be an on-going program performed with the frequency necessary to ensure that the investigation is conducted according to the investigational plan, FDA regulations, and any conditions of approval required by the FDA or the reviewing IRB. Inadequate monitoring can lead to reporting of inaccurate data, missing data, enrollment of subjects that do not meet eligibility criteria, and poor adverse event reporting, among other concerns. In addition, without adequate monitoring there is no assurance that your study conduct is compliant and that any instances of noncompliance are resolved properly.\u003C\u002Fp>\u003Cp>This was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. Your response includes a retrospectively-created CMP, new Standard Operating Procedures (SOPs) for clinical monitoring, clinical site selection, and site initiation, and revised Site Visit Logs for both clinical investigation sites. Your response indicates that the retrospectively-created CMP reflects the monitoring practices that were followed during the study conduct and indicates that the updated Site Visit Log added visits that occurred for SIV training for both clinical investigation sites, but were not present on the initial Site Visit Log. You did not provide SIV Monitoring Visit Reports for the additional SIV training conducted for both clinical investigation sites that were added to the Site Visit Logs. You also did not provide the interim monitoring reports for both clinical investigation sites that document the activities that occurred during the interim monitoring visits, nor did you provide the follow-up communication to the investigator\u002Fstudy personnel that discusses visit findings, outstanding action items, and requests for additional information. These items are needed to assess the adequacy of the monitoring conducted for this study.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to secure clinical investigator’s compliance with the signed agreement, the investigational plan, applicable FDA regulations, and any other conditions of approval imposed by the reviewing IRB or FDA, or if compliance could not be obtained, failure to discontinue shipments of the device to the investigator and terminate the investigator’s participation in the investigation [21 CFR 812.46(a)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As part of monitoring responsibilities, a sponsor is responsible for securing the investigator’s compliance with the investigational plan to ensure adherence with the study protocol and other regulatory requirements. You failed to obtain and secure the clinical investigator’s compliance with the investigational plan and applicable FDA regulations. Examples include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>a. Forty (40) subjects had baseline laboratory results indicating thrombocytopenia or no baseline platelet laboratory results. As a result, these subjects met exclusion criterion # 9, which lists subjects with a coagulation disorder, thrombocytopenia, liver disease and anti-thrombin therapy as not eligible for study. You did not ensure that investigators properly enrolled subjects according to the investigational plan.\u003C\u002Fp>\u003Cp>b. According to your Protocol Deviation Log, there were three (3) subjects whose informed consent forms were not signed by the subject, which violates inclusion criterion # 4, as well as 21 CFR 812.100, which requires that investigators obtain informed consent in accordance with 21 CFR Part 50. You did not ensure that investigators obtained informed consent according to the investigational plan and applicable FDA regulations.\u003C\u002Fp>\u003Cp>Securing clinical investigator compliance is a critical component of monitoring and is critical for ensuring the safety and welfare of study subjects. Failure to secure compliance impacts the reliability and quality of the data resulting from the study and in turn adversely impacts FDA’s ability to assess the overall safety and effectiveness of the device. As you failed to conduct proper monitoring, you did not identify that enrollment criteria were violated or that informed consent was not properly obtained, and also did not take steps to secure compliance with these requirements. Having failed to secure the investigator’s compliance, you also did not discontinue shipments of the device to the investigator and terminate the investigator’s participation in the investigation.\u003C\u002Fp>\u003Cp>This was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. While your response acknowledged the issue of enrolling subjects that did not meet the eligibility criteria related to thrombocytopenia and provided a comprehensive corrective action and preventative action plan, you have not addressed the issue of failing to obtain informed consent. Specifically, you did not provide any root cause analysis regarding the informed consent protocol deviations. You also did not identify any corrective or preventative actions taken to ensure that informed consent is properly obtained by investigators such that human subjects are adequately protected.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to immediately conduct an evaluation of any unanticipated adverse device effects and failure to report results of such an evaluation to FDA and to all reviewing IRB’s and participating investigators within 10 working days [21 CFR 812.46(b)(1) and 21 CFR 812.150(b)(1)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As a sponsor, you are responsible for conducting an evaluation of any adverse device effects that are reported as serious and unanticipated to ensure adverse events are adequately recorded and reported, and that appropriate follow-up occurs. You failed to conduct these evaluations. Examples include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>a. You failed to evaluate the unanticipated adverse device effect (UADE) for subject 02-0074 that occurred on April 30, 2019. Information for this UADE was recorded in an Adverse Event (AE) Form; however, there is no documentation to show that the UADE was evaluated as required by 21 CFR 812.46(b)(1) and study protocol, UHP001, section, 9.8.2.\u003C\u002Fp>\u003Cp>b. You failed to evaluate the UADE for subject 02-0074 that occurred on May 12, 2019. Information for this UADE was recorded in an AE Form; however, there is no documentation to show that the UADE was evaluated as required by 21 CFR 812.46(b)(1) and study protocol, UHP001, section, 9.8.2.\u003C\u002Fp>\u003Cp>Proper evaluation of UADEs, as required by 812.46(b)(1), is a critical step in ensuring the safety and welfare of study subjects. Appropriate review and evaluation of UADEs and their resolution allows for any necessary changes to be made to the investigational plan to protect study participants. Furthermore, the regulations under 812.150(b)(1) require that a sponsor who conducts an evaluation of an unanticipated adverse device effect under 812.46(b) report the results of such evaluation to FDA. Proper evaluation and timely reporting to FDA of the result of any evaluation of a UADE is important for FDA’s assessment of the overall safety profile of the device.\u003C\u002Fp>\u003Cp>This was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. Your response includes a description that the clinical site did not report these AEs to the sponsor as UADEs, and that they therefore were not handled as UADEs. In addition, you provided an updated SOP (CLN-06 Adverse Event Monitoring) to include UADE reporting requirements. However, these documents do not describe how an AE designated as a UADE by an investigator on the AE paper form is reported to the sponsor. It appears that the designation of an AE as a UADE is not captured in the electronic case report form (eCRF) and therefore these two AEs were not reported to the sponsor as UADEs, despite being identified by the investigator as such. As a result, these two AEs were not properly evaluated to determine whether they met the definition of a UADE, as required by the study protocol, UHP001, sections 9.1 and 9.8. Neither the updated SOP nor the protocol provide adequate detail to prevent a recurrence of this scenario in future studies. In addition, you did not provide source documentation for subject 02-0074 that was obtained according to Section 9.4 of the study protocol, UHP001, to assess the causal relationship between the AE and the investigational device. This documentation is needed to ensure that you have adequately conducted an evaluation of reported AEs as expected in the UHP001 study protocol. Although in this case, these two AEs were ultimately determined not to be UADEs through your postinspection activities, timely investigation of UADEs identified by study investigators while the study is ongoing is required by 21 CFR 812.46(b)(1) and a critical element of good clinical practices and does not appear to be assured by your corrective actions.\u003C\u002Fp>\u003Cp>Finally, section 7.6.1 of your updated SOP provides UADE reporting requirements and suggests that the requirement only applies to IDE studies. The evaluation requirement under 812.46 and reporting requirement under 812.150(b)(1) for UADEs also apply to non-significant risk studies subject to abbreviated requirements per 812.2(b), not just studies being conducted under an IDE. The regulatory requirements should be clarified and corrected in the SOP.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to maintain accurate, complete, and current device shipment and disposition records [21 CFR 812.140(b)(2)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As a sponsor, you are responsible for maintaining accurate, complete, and current records relating to an investigation. Specifically, records of shipment must include the name and address of the consignee, type and quantity of device, date of shipment, and batch number or code mark, and records of disposition must describe the batch number or code marks of any devices returned to the sponsor, repaired, or disposed of in other ways by the investigator or another person, and the reasons for and method of disposal. You failed to maintain the necessary records. Examples include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>a. You failed to maintain records of investigational devices received by a sponsor employee, investigational devices returned to the sponsor, or unused investigational devices disposed of for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> investigational device units packaged.\u003C\u002Fp>\u003Cp>b. You failed to maintain accurate device accountability records for both clinical investigation sites. For example, your Master Device Accountability Log documented that there were 230 subjects who received the investigational device in site # 01 and 4 subjects who received the investigational device in site # 02, with zero returned devices. However, there were only a total of 118 subjects randomized to receive the investigational device and the other subjects were assigned to the control group. In addition, the UHP001 Inventory Log for Site # 02 indicated that only 1 device was used, but the Master Device Accountability Log documented that there were 4 devices used.\u003C\u002Fp>\u003Cp>Proper records of device shipment and disposition are necessary for control of devices and to confirm that the investigational device is used only by qualified investigators on subjects appropriately enrolled in the study. If the devices were used by unqualified individuals on patients not enrolled in the study, there would be an increased risk of harm to both the user and patient.\u003C\u002Fp>\u003Cp>This was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. Your response provided a SOP for investigational device management and a corrected Master Accountability Log. However, you did not provide source documentation of study subjects’ randomization assignment to verify the changes made to the Master Accountability Log and to demonstrate that device usage was appropriate.\u003C\u002Fp>\u003Cp>The violations described above are not intended to be an all-inclusive list of problems that may exist with your clinical study. It is your responsibility as a study sponsor to ensure compliance with the Act and applicable regulations.\u003C\u002Fp>\u003Cp>Within 15 working days of receiving this letter, please provide documentation of the additional corrective and preventative actions that you have taken or will take to correct these violations and to prevent the recurrence of similar violations in current or future studies for which you are the study sponsor. Any submitted corrective action plan must include projected completion dates for each action to be accomplished as well as a plan for monitoring the effectiveness of your corrective actions. Failure to respond to this letter and take appropriate corrective action could result in the FDA taking regulatory action without further notice to you.\u003C\u002Fp>\u003Cp>Your response should reference “CTS# \u003Cstrong>(b)(4)\u003C\u002Fstrong>” and be sent via email to: Irfan.Khan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>A copy of this letter has been sent to FDA’s OII BIMO Division 1 via email OIIBIMODivision1Correspondence@fda.hhs.gov. Please send a copy of your response to that office.\u003C\u002Fp>\u003Cp>The Division of Clinical Policy and Quality has developed introductory training modules in FDA-regulated device clinical research practices, which are available on the FDA website. The modules are for persons involved in FDA-regulated device clinical research activities. These modules are located at the following website address: http:\u002F\u002Fwww.fda.gov\u002FTraining\u002FCDRHLearn\u002F.\u003C\u002Fp>\u003Cp>If you have any questions, please contact Alejandra Cambonchi by phone at (301) 796-0552 or email at Alejandra.Cambonchi@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Soma Kalb, PhD\u003Cbr>Director\u003Cbr>Division of Clinical Policy and Quality\u003Cbr>Office of Clinical Evidence &amp; Analysis\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nBiologics\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nBrian Thom\n\nRecipient Title\n\nCEO\n\nUnited Health Products, Inc.\n\n520 Fellowship Road, Suite #D-406\n\nMt. Laurel, NJ 08054\n\nUnited States\n\n(b)(6)@uhpcorp.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWarning Letter\nMarch 24, 2025\nDear Mr. Thom:\nThis Warning Letter is to inform you of objectionable conditions observed during the Food and Drug Administration (FDA) inspection conducted at United Health Products, Inc. from September 23, 2024, to October 4, 2024, by an investigator from the FDA’s Office of Bioresearch Monitoring Inspectorate (OBMI). This inspection was conducted to determine whether activities and procedures as sponsor in the significant risk clinical study “Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting,” for CelluSTAT Absorbable HemoStat, Premarket Approval (PMA) Application, (b)(4), complied with applicable federal regulations. The CelluSTAT Absorbable Hemostat is a device as that term is defined in section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h)(1), because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. This letter also requests prompt corrective action to address the violations cited and discusses your written response, dated October 25, 2024, to the noted violations.\nThe inspection was conducted under the Bioresearch Monitoring (BIMO) Program designed to ensure that data and information contained in requests for Investigational Device Exemptions (IDEs), PMA applications, and Premarket Notification submissions are scientifically valid and accurate. Another objective of the program is to ensure that human subjects are protected from undue hazard or risk during the course of scientific investigations.\nOur review of the inspection report prepared by OBMI revealed serious violations of Title 21, Code of Federal Regulations (CFR) Part 812 - Investigational Device Exemptions and 21 CFR Part 50 - Protection of Human Subjects, which concern requirements prescribed under section 520(g) of the Act, 21 U.S.C. § 360j(g). At the close of the inspection, the FDA investigator presented an inspectional observations Form FDA-483 for your review and discussed the observations listed on the form with you. The deviations noted on Form FDA-483, your written response, and our subsequent review of the inspection report are discussed below:\n1. Failure to submit an IDE application to FDA and failure to obtain FDA approval prior to beginning an investigation for which FDA’s approval is required [21 CFR 812.20(a)(1) and (2).\nSponsors must submit an IDE application to the FDA if the sponsor intends to use a significant risk device in a clinical investigation. In addition, a sponsor may not begin an investigation for which FDA’s approval of an application is required until FDA has approved the application. You did not submit an IDE application to FDA or obtain FDA approval prior to beginning such an investigation.\nYou conducted your study, UHP001, without submission and approval of an IDE application to FDA. The Western Copernicus Group (WCG) Institutional Review Board (IRB) determined that the procedures in the research posed a potential significant risk to subjects and requested documentation of the FDA’s non-significant risk (NSR) determination in multiple communications. You provided to the IRB FDA written feedback for (b)(4) and FDA meeting minutes for (b)(4), which had been modified from the FDA official correspondence by removal of references to future IDE submission and by addition of language that purported to indicate FDA agreement that the study was non-significant risk (NSR). In particular, you provided the transmittal email from FDA along with these meeting minutes, which imply that the meeting minutes that you submitted to the IRB were those provided by FDA to you as the official record. The IRB used this documentation, which misrepresented the FDA risk determination for this study, to support their determination of the regulatory status of the study, and to review and approve this study without FDA oversight.\nFDA maintains that the study UHP0001 that you have conducted to support (b)(4) as a Class III device is considered a significant risk device clinical investigation for which you should have submitted an IDE application to FDA and obtained FDA approval prior to initiation. Your device is an absorbable hemostat intended to be used as an adjunct to primary hemostasis in surgical procedures to assist in controlling capillary, venous and small arterial hemorrhage when other conventional methods are ineffective or impractical. Absorbable hemostatic agents are intended to be absorbed into the body and are Class III devices per 21 CFR 878.4490. The agency considers such devices to be significant risk devices because they are absorbed internally and present “a potential for serious risk to the health, safety, or welfare of a subject” per 21 CFR 812.3(m). 21 CFR 812.20(a) requires any sponsor who intends to use a significant risk device in an investigation to submit an application to FDA, and to wait to begin the investigation until FDA has approved the application. FDA approval of an IDE application helps to ensure subject safety and that the risks associated with the device and study procedures are minimized.\nThis was conveyed to you in the Form FDA-483, and your response dated October 25, 2024 is inadequate. Your written response includes a discussion of the interactions with FDA regarding this study and describes your misunderstanding of those interactions and of NSR\u002Fsignificant risk studies. It indicates that the meeting minutes for (b)(4) that you had provided to the IRB were your modifications to the minutes received from FDA and that you had informally emailed them to FDA. However, there is no record of your submission of these revised meeting minutes to FDA either by email or with a Meeting Minutes Disagreement amendment, the procedure outlined in FDA’s transmittal email for handling changes to meeting minutes. Importantly, there is also no agreement by FDA on these meeting minutes that you had revised. Your response also does not speak to the modifications that were made to the official FDA correspondence for (b)(4), where you inserted the word “NSR” in describing the name of the study and removed references to a (b)(4). FDA is greatly concerned about your misrepresentation of the FDA’s stance regarding the risk determination of the study to the IRB, which resulted in you inappropriately conducting this study without submitting and obtaining approval of an IDE application from FDA prior to initiation.\n2. Failure to ensure proper monitoring of the investigation [21 CFR 812.40].\nSponsors are responsible for ensuring that a clinical investigation is properly monitored. However, you failed to properly monitor your clinical investigation. Examples include, but are not limited to, the following:\na. Although you had described in the study protocol, UHP001, sections 10 and 14.9, that details regarding monitoring would be provided in the study specific Monitoring Plan and clinical site monitoring would be documented in a Clinical Monitoring Plan (CMP), respectively, you did not have an effective and implemented CMP during study conduct.\nb. You did not maintain adequate documentation regarding those monitoring activities that did occur:\ni. You failed to maintain adequate site initiation visit (SIV) documentation for the two clinical investigation sites. There were several discrepancies in documentation of SIV Monitoring Visit Reports, investigator site’s personnel training logs (SIV Training Logs), and Site Visit Logs. For example, the SIV Monitoring Visit Report for site 01 documented the visit was held on-site on December 17, 2018, with the clinical investigator and research coordinator. However, the SIV Training Log for site 01 documented the clinical investigator received SIV training on December 10, 2018, and the research coordinator received SIV training on March 19, 2019. The Site Visit Log for site 01 documented a single SIV date as December 19, 2018.\nii. You failed to maintain adequate interim monitoring documentation for the two clinical investigation sites. For example, the Site Visit Log for site 01 documented the interim monitoring visit was held on-site on July 9, 2019, but there was no interim monitoring report for this visit. In addition, the site visit log for site 02 documented the interim monitoring visit was held on-site on September 10, 2019, but there was no interim monitoring report for this visit.\nProper monitoring helps ensure that the safety, rights, and well-being of the subjects are protected, and that the data are complete and accurate. Monitoring should be an on-going program performed with the frequency necessary to ensure that the investigation is conducted according to the investigational plan, FDA regulations, and any conditions of approval required by the FDA or the reviewing IRB. Inadequate monitoring can lead to reporting of inaccurate data, missing data, enrollment of subjects that do not meet eligibility criteria, and poor adverse event reporting, among other concerns. In addition, without adequate monitoring there is no assurance that your study conduct is compliant and that any instances of noncompliance are resolved properly.\nThis was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. Your response includes a retrospectively-created CMP, new Standard Operating Procedures (SOPs) for clinical monitoring, clinical site selection, and site initiation, and revised Site Visit Logs for both clinical investigation sites. Your response indicates that the retrospectively-created CMP reflects the monitoring practices that were followed during the study conduct and indicates that the updated Site Visit Log added visits that occurred for SIV training for both clinical investigation sites, but were not present on the initial Site Visit Log. You did not provide SIV Monitoring Visit Reports for the additional SIV training conducted for both clinical investigation sites that were added to the Site Visit Logs. You also did not provide the interim monitoring reports for both clinical investigation sites that document the activities that occurred during the interim monitoring visits, nor did you provide the follow-up communication to the investigator\u002Fstudy personnel that discusses visit findings, outstanding action items, and requests for additional information. These items are needed to assess the adequacy of the monitoring conducted for this study.\n3. Failure to secure clinical investigator’s compliance with the signed agreement, the investigational plan, applicable FDA regulations, and any other conditions of approval imposed by the reviewing IRB or FDA, or if compliance could not be obtained, failure to discontinue shipments of the device to the investigator and terminate the investigator’s participation in the investigation [21 CFR 812.46(a)].\nAs part of monitoring responsibilities, a sponsor is responsible for securing the investigator’s compliance with the investigational plan to ensure adherence with the study protocol and other regulatory requirements. You failed to obtain and secure the clinical investigator’s compliance with the investigational plan and applicable FDA regulations. Examples include, but are not limited to, the following:\na. Forty (40) subjects had baseline laboratory results indicating thrombocytopenia or no baseline platelet laboratory results. As a result, these subjects met exclusion criterion # 9, which lists subjects with a coagulation disorder, thrombocytopenia, liver disease and anti-thrombin therapy as not eligible for study. You did not ensure that investigators properly enrolled subjects according to the investigational plan.\nb. According to your Protocol Deviation Log, there were three (3) subjects whose informed consent forms were not signed by the subject, which violates inclusion criterion # 4, as well as 21 CFR 812.100, which requires that investigators obtain informed consent in accordance with 21 CFR Part 50. You did not ensure that investigators obtained informed consent according to the investigational plan and applicable FDA regulations.\nSecuring clinical investigator compliance is a critical component of monitoring and is critical for ensuring the safety and welfare of study subjects. Failure to secure compliance impacts the reliability and quality of the data resulting from the study and in turn adversely impacts FDA’s ability to assess the overall safety and effectiveness of the device. As you failed to conduct proper monitoring, you did not identify that enrollment criteria were violated or that informed consent was not properly obtained, and also did not take steps to secure compliance with these requirements. Having failed to secure the investigator’s compliance, you also did not discontinue shipments of the device to the investigator and terminate the investigator’s participation in the investigation.\nThis was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. While your response acknowledged the issue of enrolling subjects that did not meet the eligibility criteria related to thrombocytopenia and provided a comprehensive corrective action and preventative action plan, you have not addressed the issue of failing to obtain informed consent. Specifically, you did not provide any root cause analysis regarding the informed consent protocol deviations. You also did not identify any corrective or preventative actions taken to ensure that informed consent is properly obtained by investigators such that human subjects are adequately protected.\n4. Failure to immediately conduct an evaluation of any unanticipated adverse device effects and failure to report results of such an evaluation to FDA and to all reviewing IRB’s and participating investigators within 10 working days [21 CFR 812.46(b)(1) and 21 CFR 812.150(b)(1)].\nAs a sponsor, you are responsible for conducting an evaluation of any adverse device effects that are reported as serious and unanticipated to ensure adverse events are adequately recorded and reported, and that appropriate follow-up occurs. You failed to conduct these evaluations. Examples include, but are not limited to, the following:\na. You failed to evaluate the unanticipated adverse device effect (UADE) for subject 02-0074 that occurred on April 30, 2019. Information for this UADE was recorded in an Adverse Event (AE) Form; however, there is no documentation to show that the UADE was evaluated as required by 21 CFR 812.46(b)(1) and study protocol, UHP001, section, 9.8.2.\nb. You failed to evaluate the UADE for subject 02-0074 that occurred on May 12, 2019. Information for this UADE was recorded in an AE Form; however, there is no documentation to show that the UADE was evaluated as required by 21 CFR 812.46(b)(1) and study protocol, UHP001, section, 9.8.2.\nProper evaluation of UADEs, as required by 812.46(b)(1), is a critical step in ensuring the safety and welfare of study subjects. Appropriate review and evaluation of UADEs and their resolution allows for any necessary changes to be made to the investigational plan to protect study participants. Furthermore, the regulations under 812.150(b)(1) require that a sponsor who conducts an evaluation of an unanticipated adverse device effect under 812.46(b) report the results of such evaluation to FDA. Proper evaluation and timely reporting to FDA of the result of any evaluation of a UADE is important for FDA’s assessment of the overall safety profile of the device.\nThis was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. Your response includes a description that the clinical site did not report these AEs to the sponsor as UADEs, and that they therefore were not handled as UADEs. In addition, you provided an updated SOP (CLN-06 Adverse Event Monitoring) to include UADE reporting requirements. However, these documents do not describe how an AE designated as a UADE by an investigator on the AE paper form is reported to the sponsor. It appears that the designation of an AE as a UADE is not captured in the electronic case report form (eCRF) and therefore these two AEs were not reported to the sponsor as UADEs, despite being identified by the investigator as such. As a result, these two AEs were not properly evaluated to determine whether they met the definition of a UADE, as required by the study protocol, UHP001, sections 9.1 and 9.8. Neither the updated SOP nor the protocol provide adequate detail to prevent a recurrence of this scenario in future studies. In addition, you did not provide source documentation for subject 02-0074 that was obtained according to Section 9.4 of the study protocol, UHP001, to assess the causal relationship between the AE and the investigational device. This documentation is needed to ensure that you have adequately conducted an evaluation of reported AEs as expected in the UHP001 study protocol. Although in this case, these two AEs were ultimately determined not to be UADEs through your postinspection activities, timely investigation of UADEs identified by study investigators while the study is ongoing is required by 21 CFR 812.46(b)(1) and a critical element of good clinical practices and does not appear to be assured by your corrective actions.\nFinally, section 7.6.1 of your updated SOP provides UADE reporting requirements and suggests that the requirement only applies to IDE studies. The evaluation requirement under 812.46 and reporting requirement under 812.150(b)(1) for UADEs also apply to non-significant risk studies subject to abbreviated requirements per 812.2(b), not just studies being conducted under an IDE. The regulatory requirements should be clarified and corrected in the SOP.\n5. Failure to maintain accurate, complete, and current device shipment and disposition records [21 CFR 812.140(b)(2)].\nAs a sponsor, you are responsible for maintaining accurate, complete, and current records relating to an investigation. Specifically, records of shipment must include the name and address of the consignee, type and quantity of device, date of shipment, and batch number or code mark, and records of disposition must describe the batch number or code marks of any devices returned to the sponsor, repaired, or disposed of in other ways by the investigator or another person, and the reasons for and method of disposal. You failed to maintain the necessary records. Examples include, but are not limited to, the following:\na. You failed to maintain records of investigational devices received by a sponsor employee, investigational devices returned to the sponsor, or unused investigational devices disposed of for the (b)(4) investigational device units packaged.\nb. You failed to maintain accurate device accountability records for both clinical investigation sites. For example, your Master Device Accountability Log documented that there were 230 subjects who received the investigational device in site # 01 and 4 subjects who received the investigational device in site # 02, with zero returned devices. However, there were only a total of 118 subjects randomized to receive the investigational device and the other subjects were assigned to the control group. In addition, the UHP001 Inventory Log for Site # 02 indicated that only 1 device was used, but the Master Device Accountability Log documented that there were 4 devices used.\nProper records of device shipment and disposition are necessary for control of devices and to confirm that the investigational device is used only by qualified investigators on subjects appropriately enrolled in the study. If the devices were used by unqualified individuals on patients not enrolled in the study, there would be an increased risk of harm to both the user and patient.\nThis was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. Your response provided a SOP for investigational device management and a corrected Master Accountability Log. However, you did not provide source documentation of study subjects’ randomization assignment to verify the changes made to the Master Accountability Log and to demonstrate that device usage was appropriate.\nThe violations described above are not intended to be an all-inclusive list of problems that may exist with your clinical study. It is your responsibility as a study sponsor to ensure compliance with the Act and applicable regulations.\nWithin 15 working days of receiving this letter, please provide documentation of the additional corrective and preventative actions that you have taken or will take to correct these violations and to prevent the recurrence of similar violations in current or future studies for which you are the study sponsor. Any submitted corrective action plan must include projected completion dates for each action to be accomplished as well as a plan for monitoring the effectiveness of your corrective actions. Failure to respond to this letter and take appropriate corrective action could result in the FDA taking regulatory action without further notice to you.\nYour response should reference “CTS# (b)(4)” and be sent via email to: Irfan.Khan@fda.hhs.gov.\nA copy of this letter has been sent to FDA’s OII BIMO Division 1 via email OIIBIMODivision1Correspondence@fda.hhs.gov. Please send a copy of your response to that office.\nThe Division of Clinical Policy and Quality has developed introductory training modules in FDA-regulated device clinical research practices, which are available on the FDA website. The modules are for persons involved in FDA-regulated device clinical research activities. These modules are located at the following website address: http:\u002F\u002Fwww.fda.gov\u002FTraining\u002FCDRHLearn\u002F.\nIf you have any questions, please contact Alejandra Cambonchi by phone at (301) 796-0552 or email at Alejandra.Cambonchi@fda.hhs.gov.\nSincerely yours,\n\u002FS\u002F\nSoma Kalb, PhD\nDirector\nDivision of Clinical Policy and Quality\nOffice of Clinical Evidence & Analysis\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","United Health Products, Inc.","united-health-products-inc-697777-03242025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funited-health-products-inc-697777-03242025","2026-10-26T08:10:17.734231+00:00","Warning Letter","Issued","2025-05-20","697777","BiologicsMedical Devices","Brian Thom","2026-08-19T16:46:50.292+00:00","2025-03-24",{"id":31,"raw":32,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":49,"recipient_name":50,"body_fetched_at":51,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},1537,[33,34,35,36,37,13,13,13],"\u003Ctime datetime=\"2024-04-02T13:20:00Z\">04\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-12-05T05:00:00Z\">12\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fambaya-gold-health-products-llc-648130-12052023\">Ambaya Gold Health Products, LLC\u003C\u002Fa>"," Division of Human and Animal Food Operations West IV","Unapproved New Drugs\u002FMisbranded ","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Pilar G. Martin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Ambaya Gold Health Products, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10 Gideon Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sedona\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>86336\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations West IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 5, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Reference: CMS Case # 648130\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Martin:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the U. S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.ambayagold.com in April and November 2023 and has determined that you take orders for the products Brain Balance, Immune System Boost, Dentist In A Bottle, Essensiac, Fulvic Green, Silver Solution, Detox Cleanse Renew, Magnesium Oil Spray, Silver Spray, and Pet Health+. We also reviewed your social media website at www.facebook.com\u002FAmbayaGoldHealth, which directs consumers to your website at www.ambayagold.com to purchase your products. The claims on your websites establish these products are drugs under section 201(g)(1)(B)\u002F(C) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. §§ 321(g)(1)(B)\u002F(C)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. As explained further below, introducing or delivering these products for introduction into interstate commerce violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Brain Balance product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Brain Balance product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fbrain-balance-regeneration):\u003C\u002Fp>\n\n\u003Cp>• “Lithium orotate [an ingredient in Brain Balance] …great natural treatment for a wide range of mental health problems.”\u003Cbr>\n\u003Cbr>\nOn the “What is Ashwagandha?” blog post, dated June 20, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fwhat_is_ashwagandha), which contains a hyperlink to purchase Brain Balance:\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Benefits of Top Rated Ashwagandha Supplements”:\u003Cbr>\n&nbsp; &nbsp; − “1. Powerful anti-inflammatory…”\u003Cbr>\n&nbsp; &nbsp; − “7. Reduce symptoms of depression”\u003Cbr>\n&nbsp; &nbsp; − “8. Lower cholesterol and triglycerides”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated June 20, 2022:\u003C\u002Fp>\n\n\u003Cp>• Under the heading “HEALTH BENEFITS OF ASHWAGANDHA” [an ingredient in Brain Balance]:\u003Cbr>\n&nbsp; &nbsp; − “REDUCES BLOOD SUGAR LEVELS…helps in [sic] increased insulin secre-tion and improved insu-lin sensitivity.”\u003Cbr>\n&nbsp; &nbsp; − “HELPS FIGHT CANCER…helps in reducing the growth of tumors, prevents cancer cells from growing”\u003Cbr>\n&nbsp; &nbsp; − “IMPROVES THY-ROID FUNCTION…benefits people suffer-ing from hypothyroid-ism…”\u003Cbr>\n&nbsp; &nbsp; − “REDUCES SYMP-TOMS OF DEPRES-SION… plays an essential role in reducing depression”\u003Cbr>\n&nbsp; &nbsp; − “MAY LOWER CHO-LESTEROL AND TRI-GLYCERIDES…helps lower LDL, and VDL cholesterol and triglyceride levels and increase HDL levels.”\u003Cbr>\n&nbsp; &nbsp; − “CAN PREVENT SEI-ZURES…used in traditional ayurvedic medi-cines as a cure for sei-zures and convulsions.”\u003Cbr>\n&nbsp; &nbsp; − “[P]revents loss of bone mineral density and reduces bone reabsorp-tion.”\u003Cbr>\n&nbsp; &nbsp; − “[H]elp prevent chronic eye diseases.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Immune System Boost product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the “Combating Allergies (The Holistic Way)” blog post, dated October 31, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fcombating-allergies-the-holistic-way), which contains a hyperlink to purchase Immune System Boost:\u003Cbr>\n\u003Cbr>\n• “There are natural allergy remedies that have very little to no side effects and can be as effective (if not more) than allergy medications.”\u003Cbr>\n• “If you find yourself constantly effected[sic] by allergies, check out our Immune System Boost.”\u003Cbr>\n• “MSM [an ingredient in Immune System Boost] can decrease allergic reactions by lowering inflammation and inhibiting the release of cytokines and prostaglandins thanks to its anti-inflammatory and antioxidant effects. It binds to the mucosa, blocking host and allergen contact.”\u003Cbr>\n• “Silver [an ingredient in Immune System Boost] …well documented natural antibacterial.”\u003C\u002Fp>\n\n\u003Cp>On the “Keep your Immune System Naturally Strong During Flu Season” blog post, dated October 24, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fkeep-your-immune-system-naturally-strong-during-flu-season), which contains a hyperlink to purchase Immune System Boost:\u003C\u002Fp>\n\n\u003Cp>• “Silver [an ingredient in Immune System Boost] …well documented natural antibacterial.”\u003C\u002Fp>\n\n\u003Cp>On the “Naturally Strengthen Your Immune System” blog post, dated February 3, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fnaturally-strengthen-your-immune-system), which contains a hyperlink to purchase Immune System Boost:\u003C\u002Fp>\n\n\u003Cp>• “Ambaya Gold’s Immune Boost [this phrase hyperlinks to the Immune System Boost product page] is…anti-microbial, anti-viral...”\u003C\u002Fp>\n\n\u003Cp>On the “Top Science-Backed Benefits of MSM” blog post, dated October 10, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Ftop-science-backed-benefits-of-msm), which contains a hyperlink to purchase Immune System Boost:\u003C\u002Fp>\n\n\u003Cp>• “Have you heard about MSM [an ingredient in Immune System Boost] …it can help with a variety of conditions, like arthritis and joint pain.”\u003Cbr>\n• Under the heading “Ten Reasons You Should Consider Taking MSM” [an ingredient in Immune System Boost]:\u003Cbr>\n&nbsp; &nbsp; − “2. MSM May Have Anti-inflammatory Effects…may reduce the release of molecules linked to inflammation…inhibits NF-kB, a protein complex involved in inflammatory responses in the body…reduces production of cytokines such as TNF-a and IL-6, which are signaling proteins linked to systemic inflammation.”\u003Cbr>\n&nbsp; &nbsp; − “3. MSM May Treat Arthritis and Joint Pain…Arthritis is probably the most known condition that MSM is used for, especially osteoarthritis. …MSM might lessen the pain associated with it. One study of 100 people…found that treatment with a supplement containing MSM for 12 weeks lessened pain, stiffness and swelling in the joints, compared to a placebo.”\u003Cbr>\n&nbsp; &nbsp; − “4. MSM May Help with Digestive Problems…may improve symptoms in patients with Leaky Gut Syndrome…One study, however, did show oral intake of MSM assisted in protecting gut damage in rats with colitis. MSM supplements may also reduce swelling and discomfort caused by hemorrhoids.”\u003Cbr>\n&nbsp; &nbsp; − “8. MSM May Relieve Allergies…MSM can decrease allergic reactions by lowering inflammation and inhibiting the release of cytokines and prostaglandins thanks to its anti-inflammatory. …It was found that allergy symptoms and lower respiratory symptoms were reduced in people with seasonal allergic rhinitis after taking MSM supplementation for one month.”\u003Cbr>\n&nbsp; &nbsp; − “9. MSM May Help With Parasites…may be an effective treatment for worms, giardia and trichomonas. …MSM coats the gut lining making it impossible for parasites to attach themselves. They are then naturally flushed out of the body. Candida is when the body experiences an overgrowth in fungus which can cause various health problems. MSM changes the PH in your body where Candida can not [sic] thrive in.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Essensiac product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Essensiac product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fessensiac):\u003C\u002Fp>\n\n\u003Cp>• On the image of your product label:\u003Cbr>\n&nbsp; &nbsp; − “[E]ssiac tea…for…reducing inflammation”\u003Cbr>\n• “Slippery Elm Bark [an ingredient in Essensiac]… can provide anti-inflammatory support.”\u003C\u002Fp>\n\n\u003Cp>On the “Honoring the Benefits of Slippery Elm Tree” blog post, dated November 7, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fhonoring-the-benefits-of-slippery-elm-tree), which contains a hyperlink to purchase Essensiac:\u003C\u002Fp>\n\n\u003Cp>• “[H]ealth benefits of slippery elm bark [an ingredient in Essensiac] come from the biochemical compounds that are extracted from it. They include mucilage…[m]ucilage: Helps to soothe sore throats and suppress coughs…”\u003Cbr>\n• “Tannins [a component of the slippery elm bark ingredient in the Essensiac product]: Contains…anti-inflammatory properties. Helps lower cholesterol, lower blood pressure…It also has antibacterial properties that help fight tooth decay.”\u003Cbr>\n• “Sterols [a component of the slippery elm bark ingredient in the Essensiac product]: Plant sterols can help to lower cholesterol and prevent cardiovascular disease…”\u003Cbr>\n• “[A]nti-inflammatory properties of fatty acids, tannins and plant sterols [components of the slippery elm bark ingredient in the Essensiac product] …may all contribute to Slippery Elm Bark’s use as an alternative anti-inflammation aid for some chronic conditions.”\u003Cbr>\n• “…Slippery Elm (Ulmus fulva) [an ingredient in Essensiac] has been used…for help with a variety of health conditions, including: …Sore throat…Cough…Other chronic conditions that develop from inflammation”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated November 7, 2022:\u003C\u002Fp>\n\n\u003Cp>• “[S]lippery Elm (Ulmus fulva) [an ingredient in Essensiac] has been used…to help with a variety of health conditions, including: …Sore throat…Cough…Other chronic conditions that develop from inflammation”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated February 4, 2022:\u003C\u002Fp>\n\n\u003Cp>• “It assists the body to create an environment that fights against dis-ease…”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated May 14, 2021:\u003C\u002Fp>\n\n\u003Cp>• “My morning routine includes…Essensiac for its…anti-inflammatory properties....”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Dentist In A Bottle product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Dentist In A Bottle product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fdentist-in-a-bottle):\u003C\u002Fp>\n\n\u003Cp>• “Assistance with the prevention of tooth decay”\u003Cbr>\n• “By reducing harmful bacteria growth and replacing essential minerals, Dentist in a Bottle…assists in the prevention and remediation of gum and tooth decay.”\u003Cbr>\n• “I bought Dentist in a Bottle because my dentist told me I needed a root canal…used it twice a day, soaking the area for about two minutes. The pain and infection subsided after one day and disappeared after one week. A new dentist said that I did not need a root canal…”\u003Cbr>\n• “…[A]lways had problems with my teeth and gums…led to lifelong chronic gum and tooth infections . . . has completely removed the plaque buildup and now my teeth and gums feel clean and healthy…my gums have stopped bleeding. …Dentist In A Bottle”\u003C\u002Fp>\n\n\u003Cp>On the “Reasons You Should Switch to a Natural Mouthwash Today” blog post, dated September 5, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Freasons-you-should-switch-to-a-natural-mouthwash-today), which contains a hyperlink to purchase Dentist In A Bottle:\u003C\u002Fp>\n\n\u003Cp>• “Two main ingredients in our mouthwash, Dentist in a Bottle, are Fulvic and Silver. Both are known for their antibacterial properties and can be very effective at reducing harmful bacteria. Using these two together can help prevent gum disease and tooth decay.”\u003Cbr>\n• “…Effective on Bacteria”\u003Cbr>\n• “Assistance with the prevention of tooth decay”\u003Cbr>\n• “Most natural rinses, like ours, contain popular ingredients like peppermint, rosemary, thyme, cinnamon bark, eucalyptus, wintergreen, lemon, clove and birch oil. Research has proven their anti bacterial [sic], antimicrobial and anti-inflammatory properties’”\u003Cbr>\n• “‘Oral infections can result in inflammation in other parts of the body since our oral mucosa has a direct pathway to the bloodstream.’ …Our Dentist in a Bottle offers overall improvement in oral health...”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated September 5, 2022:\u003C\u002Fp>\n\n\u003Cp>• “Fulvic and Silver [ingredients in Dentist In A Bottle] are known for their antibacterial properties and can be very effective at reducing harmful bacteria.”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated June 8, 2022:\u003C\u002Fp>\n\n\u003Cp>• “By reducing harmful bacteria growth and replacing essential mineral, Dentist in a Bottle, freshens the mouth…while assisting in the prevention and remediation of gum and tooth decay.”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated July 12, 2021:\u003C\u002Fp>\n\n\u003Cp>• “Our effective mouthwash is a natural alternative to toxic mouthwashes…reduces harmful bacteria growth and replaces essential minerals!”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Fulvic Green product\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\nOn the “The Surprising Benefits of Chlorophyll” blog post, dated August 1, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fthe-surprising-benefits-of-chlorophyll), which contains a hyperlink to purchase Fulvic Green:\u003C\u002Fp>\n\n\u003Cp>• Under the heading “10 Amazing Benefits of Chlorophyll” [an ingredient in Fulvic Green]:\u003Cbr>\n&nbsp; &nbsp; − “2. [R]epair small gut wounds.”\u003Cbr>\n&nbsp; &nbsp; − “5. It’s also an excellent blood purifier that helps prevent or even reverse dis-ease [sic] in your body.”\u003C\u002Fp>\n\n\u003Cp>On the “Superfood Hawaiian Spirulina” blog post, dated June 27, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fsuperfood_hawaiian_spirulina), which contains a hyperlink to purchase Fulvic Green:\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Benefits of Spirulina” [an ingredient in Fulvic Green]:\u003Cbr>\n&nbsp; &nbsp; − “[R]educes allergy symptoms”\u003Cbr>\n&nbsp; &nbsp; − “[G]reat anti-inflammation”\u003Cbr>\n&nbsp; &nbsp; − “[C]an reduce risk of cancer”\u003Cbr>\n&nbsp; &nbsp; − “[P]revents &amp; helps with cardiovascular disease”\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Why Take Hawaiian Spirulina [an ingredient in Fulvic Green] Supplements?”:\u003Cbr>\n&nbsp; &nbsp; − “Lowers Blood Pressure…A great way to lower your blood pressure is to add spirulina to your diet.”\u003Cbr>\n&nbsp; &nbsp; − “[S]pirulina …Foods high in antioxidants have been proven to lower inflammation and eliminate free radicals which can prevent degenerative brain diseases…spirulina helps with ADHD.”\u003Cbr>\n&nbsp; &nbsp; − “Lower Blood Sugar…Spirulina can lower blood sugar levels.”\u003Cbr>\n&nbsp; &nbsp; − “Can Reduce Risk of Cancer…Adding spirulina to your diet can reduce risk of cancer. Testing…showed the spirulina increased the production of antibodies as well as infection-fighting proteins and cells that help to protect against cancer…spirulina could have potential to prevent a number of other diseases”\u003Cbr>\n&nbsp; &nbsp; − “Protect Against Liver Disease…Protection against liver disease”\u003Cbr>\n&nbsp; &nbsp; − “Detox from Heavy Metals…Spirulina acts as a detox for your body, especially from heavy metals, like arsenic. …United States is one of the countries that are most affected by arsenic poisoning. Spirulina is a natural remedy for getting rid of that arsenic and other metals that have accumulated in the body.”\u003Cbr>\n&nbsp; &nbsp; − “Reduce Cholesterol…Spirulina can greatly reduce cholesterol as well. Cholesterol can be a problem that leads to heart disease…Anyone at risk for heart disease…should consider adding spirulina to their diet.”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated August 1, 2022:\u003C\u002Fp>\n\n\u003Cp>• Under the heading “CHLOROPHYLL [an ingredient in Fulvic Green] BENEFITS”:\u003Cbr>\n&nbsp; &nbsp; − “ANTI-CARCINOGENIC”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated June 27, 2022:\u003Cbr>\n• Under the heading “Benefits of Spirulina” [an ingredient in Fulvic Green]:\u003Cbr>\n&nbsp; &nbsp; − “[R]educes allergy symptoms”\u003Cbr>\n&nbsp; &nbsp; − “[G]reat anti-inflammation”\u003Cbr>\n&nbsp; &nbsp; − “[C]an reduce risk of cancer”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Silver Solution product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Silver Solution product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fag-liquid-silver-solutions):\u003C\u002Fp>\n\n\u003Cp>• On the image of your product label:\u003Cbr>\n&nbsp; &nbsp; − [W]ide-spectrum antibacterial solution minimizes risk of infections”\u003Cbr>\n• “Silver [an ingredient in Silver Solution] is considered a very powerful antibacterial element because its ions cause inhibition of bacterial growth. Silver ions' interaction with enzymes and proteins play an important and essential role in antibacterial efficacy in the body.”\u003C\u002Fp>\n\n\u003Cp>On the “The Many Uses of Silver” blog post, dated December 27, 2021, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fthe-many-uses-of-silver), which refers to your Silver Solution product available for purchase on your website (www.ambayagold.com):\u003C\u002Fp>\n\n\u003Cp>• “Taking Silver [an ingredient in Silver Solution] orally can assist with symptoms of colds, sinus infections…can lessen the symptoms of allergies and arthritis.”\u003Cbr>\n• “Silver [an ingredient in Silver Solution] can fight hundreds of disease causing [sic] bacteria &amp; viruses...”\u003Cbr>\n• “If you don't like taking antibiotics for urinary tract or bladder infections, silver [an ingredient in Silver Solution], a natural alternative can assist to clear up your system by taking 1\u002F2 teaspoon of our Silver orally…”\u003C\u002Fp>\n\n\u003Cp>On the “What's the Difference Between Silver and Gold?” blog post, dated December 13, 2021, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fwhats-the-difference-between-silver-and-gold), which refers to your Silver Solution product available for purchase on your website (www.ambayagold.com):\u003C\u002Fp>\n\n\u003Cp>• “Silver [an ingredient in Silver Solution] ions cause inhibition of bacterial growth. Therefore they are naturally antibacterial. Silver ions, and their interaction with enzymes and proteins play an important role in antibacterial efficacy in the body.”\u003Cbr>\n• “…Silver [an ingredient in Silver Solution] can be used as a non-toxic, safe, and easy to use supplement as a natural antibiotic…”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated December 19, 2021:\u003C\u002Fp>\n\n\u003Cp>• “Silver [an ingredient in Silver Solution] is naturally antibacterial…”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Detox Cleanse Renew\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Essentials Kit webpage (https:\u002F\u002Fambayagold.com\u002Fpages\u002Fthe-essentials-kit), which contains a hyperlink to purchase Detox Cleanse Renew:\u003C\u002Fp>\n\n\u003Cp>• “RESTORE FULVIC [an ingredient in Detox Cleanse Renew] RESTORE HEALTH…Toxic build up and mineral deficiencies are two of the biggest health issues that people face today and can lead to symptoms like: …Blood Sugar Imbalances…Insomnia…”\u003Cbr>\n• “BENEFITS OF FULVIC… REDUCES INFLAMMATION …FIGHTS PATHOGENS...”\u003C\u002Fp>\n\n\u003Cp>On the “The Best Detox For Environmental Toxins And Radiation” blog post, dated July 4, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fthe_best_detox_for_environmental_toxins_and_radiation), which contains a hyperlink to purchase Detox Cleanse Renew:\u003C\u002Fp>\n\n\u003Cp>• “[C]ancers, disease and birth defects are increasing in both humans and animals due to environmental pollutants full of heavy metals and other toxins. …The best way to remove toxic heavy metals from environmental pollution and radiation from the body is by chelating them out with a product…Clinoptilolite Zeolite [an ingredient in Detox Cleanse Renew] is by far the best way to combat these toxins.”\u003Cbr>\n• “The miracle toxin magnet, Zeolite [an ingredient in Detox Cleanse Renew] …draws heavy metals and toxins to the Zeolite…enabling the toxins to be safely eliminated…”\u003Cbr>\n• “As the heavy metals and toxins are eliminated the immune system can grow strong again to better fight off viruses, bacteria and deformed cells...”\u003Cbr>\n• “Routinely detoxifying with zeolite [an ingredient in Detox Cleanse Renew] is necessary because when you’re exposed to toxins, your body stores them in your cells. Over time, toxins and radiation can build up to dangerous levels—leading to disease, chronic fatigue, brain fog and even cancer.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Silver Spray product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Silver Spray product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fag-liquid-silver-spray):\u003C\u002Fp>\n\n\u003Cp>“AMBAYA GOLD . . . SILVER SPRAY . . . wide-spectrum antibacterial solution minimizes risk of infections” [from your product label for SILVER SPRAY]\u003C\u002Fp>\n\n\u003Cp>“Silver Spray . . . Natural antibacterial . . . Disinfects like hydrogen peroxide without the burn . . .” [https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCmSADzUva93\u002F and https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002Fposts\u002Fpfbid02Hkd21pHbyrU5TL1MaAgRh1E9CJWtbKVenM5kyQaRtKtC4G9XL2ZMZZ58u7LApMGQl]\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Magnesium Oil Spray product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“Our fast acting topical Magnesium Oil Spray offers the benefits of pure Magnesium Oil in a proprietary Fulvic base. . . .This convenient spray is designed is designed to provide relief from body tension and soreness quickly and effectively. . . .For muscle cramps or pains, spray directly on problem area.” [from your product website, https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fmagnesium-oil-spray]\u003C\u002Fp>\n\n\u003Cp>Specifically, these products are intended for use as a first aid antiseptic, and an external analgesic, respectively\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your Brain Balance, Immune System Boost, Dentist In A Bottle, Essensiac, Fulvic Green, Silver Solution, and Detox Cleanse Renew products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>Further, your “Silver Spray” product, containing silver, is a first aid antiseptic subject to section 505G of the FD&amp;C Act, which governs nonprescription drugs marketed without an approved application. Specifically, your silver-containing product falls under section 505G(a)(5) of the FD&amp;C Act, because FDA has determined that no silver containing OTC drugs are generally recognized as safe and effective under a final determination issued under 21 CFR part 330.\u003Csup>\u003Cem>\u003Cstrong>2, 3&nbsp;&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>Therefore, Silver Spray is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&amp;C Act is in effect for this drug product. Accordingly, “Silver Spray” is an unapproved new drug marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section and 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>Your “Magnesium Oil Spray” is a topical external analgesic drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to OTC external analgesic drug products, such products are deemed to be GRASE and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (“M017”).\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>However, “Magnesium Oil Spray” does not conform to the conditions specified in the final administrative order for the reasons described below. Your “Magnesium Oil Spray” is not formulated and labeled as an external analgesic counterirritant drug product that is consistent with the final administrative order. Specifically, your product is labeled to contain the ingredients magnesium chloride, fulvic, indium, aloe vera, pyridoxine HCl (B6), MSM, and plant based phytonutrients, all of which are outside of the final applicable administrative order. According to 21 CFR 201.66(b)(2), an “active ingredient” means any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans. Although your firm does not specifically list these ingredients as active ingredients, your product website includes statements that claim this combination of ingredients is “designed to provide relief from body tension and soreness” as a treatment for symptoms related to magnesium deficiency that include “leg cramps and muscle soreness,” along with “migraines, insomnia, [and] fatigue.” Such statements demonstrate that those ingredients are considered “active ingredients” as defined by 21 CFR 201.66(b)(2) because this combination of ingredients is intended to furnish pharmacological activity. However, this combination of active ingredients is not permitted under the applicable final order nor are any of these ingredients permitted as a single active ingredient in an external analgesic product under the final administrative order.\u003C\u002Fp>\n\n\u003Cp>Thus, as formulated and labeled, “Magnesium Oil Spray” does not comply with the final administrative order described above or any applicable proposed or final rule. FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Magnesium Oil Spray” is GRASE for use under the conditions prescribed, recommended or suggested in its labeling. Moreover, there is no evident basis under the FD&amp;C Act under which this product would be legally marketed without an approved application. Therefore, “Magnesium Oil Spray” is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Accordingly, “Magnesium Oil Spray” is an unapproved new drug marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section and 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>In addition, “Silver Spray” and “Magnesium Oil Spray” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because they are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, are not the subject of applications approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355, and do not comply with the requirements under section 505G of the FD&amp;C Act, 21 U.S.C. 355h. Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Brain Balance, Silver Solution, Dentist In A Bottle, Essensiac, Fulvic Green, and Detox Cleanse Renew products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, the Brain Balance, Silver Solution, Dentist In A Bottle, Essensiac, Fulvic Green, and Detox Cleanse Renew products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Animal Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on our review of your website www.ambayagold.com and your social media website www.facebook.com\u002FAmbayaGoldHealth, your Pet Health+ product is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on your website and social media website that provide evidence that your product is intended for use as a drug include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Pet Health+ product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Pet Health+ product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fpet-health):\u003C\u002Fp>\n\n\u003Cp>• “Detox of heavy metals, chemicals and other toxins* Protection from worms, parasites, and fungus* Natural anti-inflammatory agents*…Protection from infection*…Accelerated wound recovery*”\u003Cbr>\n• “In our Pet Health +, our clean sourced Clinoptilolite Zeolite is formulated and suspended in a freshwater Humic and Fulvic liquid solution. The Humic helps to penetrate deep into the cells, providing a cleansing action by safely binding harmful toxins.”\u003Cbr>\n• “Why Silver and Gold? Monatomic Silver is considered a powerful natural antibacterial element because its ions cause inhibition of bacterial growth. Silver ions' interaction with enzymes and proteins play an important and essential role in antibacterial efficacy in the body.”\u003Cbr>\n• A customer testimonial from 2\u002F18\u002F2022 states, “This product has help [sic] to support for our new dog’s… anxiety issues…”\u003Cbr>\n\u003Cbr>\nOn the “Natural Remedies for Pain Relief in Dogs” blog post, dated December 5, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fnatural-remedies-for-pain-relief-in-dogs), which contains a hyperlink to purchase Pet Health+:\u003C\u002Fp>\n\n\u003Cp>• “Holistic pet supplements and pain relievers can have a wide range of benefits like: …Assistance with detox of heavy metals, chemicals, and other toxins…Protection from worms, parasites, fungus, and infection…Natural anti-inflammatory agents…Accelerated wound recovery…All of the above benefits have been reported by users of our pet multivitamin, Pet Health+ [hyperlinks to the Pet Health+ product page].\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated May 15, 2022:\u003C\u002Fp>\n\n\u003Cp>• “Pet Health+ helps…Assist with detox of heavy metals, chemicals, and other toxins…Protect from worms, parasites, fungus, and infection”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated October 8, 2021, with three photos of a cat:\u003C\u002Fp>\n\n\u003Cp>• “…[H]er cat’s obsessive grooming…This caused her to form “hot spots” where the skin had become inflamed and formed open wounds. …When modern medicine didn’t help, she tried Pet Health+ and here are her results after ONLY a week and a half!”\u003C\u002Fp>\n\n\u003Cp>Your Pet Health+ product is a \"new animal drug\" under section 201(v) of the Act [21 U.S.C. § 321(v)] because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1]. Pet Health+ is not approved, conditionally approved, or index listed by the FDA, and therefore this product is considered unsafe under section 512(a) of the Act [21 U.S.C. § 360b(a)] and adulterated under section 501(a)(5) of the Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003Cbr>\n\u003Cbr>\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your reply should be addressed to the U.S. Food and Drug Administration; Attn: Carrie Jolly, Compliance Officer, via email at carrie.jolly@fda.hhs.gov or at 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado. You may reach Ms. Jolly at carrie.jolly@fda.hhs.gov or (303) 236-9656.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>E. Mark Harris\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations –\u003Cbr>\nWest Division 4\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> It is not clear whether you intend your “Silver Spray” and “Magnesium Oil Spray” products to be marketed as dietary supplements. Your firm lists these two products on your website under the heading “Supplements.” Under section 201(ff)(2)(A)(i) of the FD&amp;C Act [21 U.S.C. § 321(ff)(2)(A)(i)], a dietary supplement is defined, among other things, as a product intended for ingestion. Topical products and other products that are not intended for ingestion cannot be dietary supplements.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 310.548(b): \"Any OTC drug product containing colloidal silver ingredients or silver salts that is labeled, represented, or promoted for the treatment and\u002For prevention of any disease is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the Act) for which an approved application or abbreviated application under section 505 of the Act and part 314 of this chapter is required for marketing. In the absence of an approved new drug application or abbreviated new drug application, such product is also misbranded under section 502 of the Act.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(8)(i). Under section 505G(k)(2)(A) of the FD&amp;C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) are deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC000007, available at OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(1) of the FD&amp;C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR. part 330 prior to enactment of the CARES Act. In the case of OTC anorectal drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nPilar G. Martin\n\nRecipient Title\n\nOwner\n\nAmbaya Gold Health Products, LLC\n\n10 Gideon Rd\n\nSedona, AZ 86336\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West IV\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nDecember 5, 2023\n\nWARNING LETTER\n\nReference: CMS Case # 648130\n\nDear Ms. Martin:\n\nThis is to advise you that the U. S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.ambayagold.com in April and November 2023 and has determined that you take orders for the products Brain Balance, Immune System Boost, Dentist In A Bottle, Essensiac, Fulvic Green, Silver Solution, Detox Cleanse Renew, Magnesium Oil Spray, Silver Spray, and Pet Health+. We also reviewed your social media website at www.facebook.com\u002FAmbayaGoldHealth, which directs consumers to your website at www.ambayagold.com to purchase your products. The claims on your websites establish these products are drugs under section 201(g)(1)(B)\u002F(C) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. §§ 321(g)(1)(B)\u002F(C)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. As explained further below, introducing or delivering these products for introduction into interstate commerce violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nUnapproved New Drugs\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nBrain Balance product\n\nOn the Brain Balance product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fbrain-balance-regeneration):\n\n• “Lithium orotate [an ingredient in Brain Balance] …great natural treatment for a wide range of mental health problems.”\n\nOn the “What is Ashwagandha?” blog post, dated June 20, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fwhat_is_ashwagandha), which contains a hyperlink to purchase Brain Balance:\n\n• Under the heading “Benefits of Top Rated Ashwagandha Supplements”:\n\n− “1. Powerful anti-inflammatory…”\n\n− “7. Reduce symptoms of depression”\n\n− “8. Lower cholesterol and triglycerides”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated June 20, 2022:\n\n• Under the heading “HEALTH BENEFITS OF ASHWAGANDHA” [an ingredient in Brain Balance]:\n\n− “REDUCES BLOOD SUGAR LEVELS…helps in [sic] increased insulin secre-tion and improved insu-lin sensitivity.”\n\n− “HELPS FIGHT CANCER…helps in reducing the growth of tumors, prevents cancer cells from growing”\n\n− “IMPROVES THY-ROID FUNCTION…benefits people suffer-ing from hypothyroid-ism…”\n\n− “REDUCES SYMP-TOMS OF DEPRES-SION… plays an essential role in reducing depression”\n\n− “MAY LOWER CHO-LESTEROL AND TRI-GLYCERIDES…helps lower LDL, and VDL cholesterol and triglyceride levels and increase HDL levels.”\n\n− “CAN PREVENT SEI-ZURES…used in traditional ayurvedic medi-cines as a cure for sei-zures and convulsions.”\n\n− “[P]revents loss of bone mineral density and reduces bone reabsorp-tion.”\n\n− “[H]elp prevent chronic eye diseases.”\n\nImmune System Boost product\n\nOn the “Combating Allergies (The Holistic Way)” blog post, dated October 31, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fcombating-allergies-the-holistic-way), which contains a hyperlink to purchase Immune System Boost:\n\n• “There are natural allergy remedies that have very little to no side effects and can be as effective (if not more) than allergy medications.”\n\n• “If you find yourself constantly effected[sic] by allergies, check out our Immune System Boost.”\n\n• “MSM [an ingredient in Immune System Boost] can decrease allergic reactions by lowering inflammation and inhibiting the release of cytokines and prostaglandins thanks to its anti-inflammatory and antioxidant effects. It binds to the mucosa, blocking host and allergen contact.”\n\n• “Silver [an ingredient in Immune System Boost] …well documented natural antibacterial.”\n\nOn the “Keep your Immune System Naturally Strong During Flu Season” blog post, dated October 24, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fkeep-your-immune-system-naturally-strong-during-flu-season), which contains a hyperlink to purchase Immune System Boost:\n\n• “Silver [an ingredient in Immune System Boost] …well documented natural antibacterial.”\n\nOn the “Naturally Strengthen Your Immune System” blog post, dated February 3, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fnaturally-strengthen-your-immune-system), which contains a hyperlink to purchase Immune System Boost:\n\n• “Ambaya Gold’s Immune Boost [this phrase hyperlinks to the Immune System Boost product page] is…anti-microbial, anti-viral...”\n\nOn the “Top Science-Backed Benefits of MSM” blog post, dated October 10, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Ftop-science-backed-benefits-of-msm), which contains a hyperlink to purchase Immune System Boost:\n\n• “Have you heard about MSM [an ingredient in Immune System Boost] …it can help with a variety of conditions, like arthritis and joint pain.”\n\n• Under the heading “Ten Reasons You Should Consider Taking MSM” [an ingredient in Immune System Boost]:\n\n− “2. MSM May Have Anti-inflammatory Effects…may reduce the release of molecules linked to inflammation…inhibits NF-kB, a protein complex involved in inflammatory responses in the body…reduces production of cytokines such as TNF-a and IL-6, which are signaling proteins linked to systemic inflammation.”\n\n− “3. MSM May Treat Arthritis and Joint Pain…Arthritis is probably the most known condition that MSM is used for, especially osteoarthritis. …MSM might lessen the pain associated with it. One study of 100 people…found that treatment with a supplement containing MSM for 12 weeks lessened pain, stiffness and swelling in the joints, compared to a placebo.”\n\n− “4. MSM May Help with Digestive Problems…may improve symptoms in patients with Leaky Gut Syndrome…One study, however, did show oral intake of MSM assisted in protecting gut damage in rats with colitis. MSM supplements may also reduce swelling and discomfort caused by hemorrhoids.”\n\n− “8. MSM May Relieve Allergies…MSM can decrease allergic reactions by lowering inflammation and inhibiting the release of cytokines and prostaglandins thanks to its anti-inflammatory. …It was found that allergy symptoms and lower respiratory symptoms were reduced in people with seasonal allergic rhinitis after taking MSM supplementation for one month.”\n\n− “9. MSM May Help With Parasites…may be an effective treatment for worms, giardia and trichomonas. …MSM coats the gut lining making it impossible for parasites to attach themselves. They are then naturally flushed out of the body. Candida is when the body experiences an overgrowth in fungus which can cause various health problems. MSM changes the PH in your body where Candida can not [sic] thrive in.”\n\nEssensiac product\n\nOn the Essensiac product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fessensiac):\n\n• On the image of your product label:\n\n− “[E]ssiac tea…for…reducing inflammation”\n\n• “Slippery Elm Bark [an ingredient in Essensiac]… can provide anti-inflammatory support.”\n\nOn the “Honoring the Benefits of Slippery Elm Tree” blog post, dated November 7, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fhonoring-the-benefits-of-slippery-elm-tree), which contains a hyperlink to purchase Essensiac:\n\n• “[H]ealth benefits of slippery elm bark [an ingredient in Essensiac] come from the biochemical compounds that are extracted from it. They include mucilage…[m]ucilage: Helps to soothe sore throats and suppress coughs…”\n\n• “Tannins [a component of the slippery elm bark ingredient in the Essensiac product]: Contains…anti-inflammatory properties. Helps lower cholesterol, lower blood pressure…It also has antibacterial properties that help fight tooth decay.”\n\n• “Sterols [a component of the slippery elm bark ingredient in the Essensiac product]: Plant sterols can help to lower cholesterol and prevent cardiovascular disease…”\n\n• “[A]nti-inflammatory properties of fatty acids, tannins and plant sterols [components of the slippery elm bark ingredient in the Essensiac product] …may all contribute to Slippery Elm Bark’s use as an alternative anti-inflammation aid for some chronic conditions.”\n\n• “…Slippery Elm (Ulmus fulva) [an ingredient in Essensiac] has been used…for help with a variety of health conditions, including: …Sore throat…Cough…Other chronic conditions that develop from inflammation”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated November 7, 2022:\n\n• “[S]lippery Elm (Ulmus fulva) [an ingredient in Essensiac] has been used…to help with a variety of health conditions, including: …Sore throat…Cough…Other chronic conditions that develop from inflammation”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated February 4, 2022:\n\n• “It assists the body to create an environment that fights against dis-ease…”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated May 14, 2021:\n\n• “My morning routine includes…Essensiac for its…anti-inflammatory properties....”\n\nDentist In A Bottle product\n\nOn the Dentist In A Bottle product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fdentist-in-a-bottle):\n\n• “Assistance with the prevention of tooth decay”\n\n• “By reducing harmful bacteria growth and replacing essential minerals, Dentist in a Bottle…assists in the prevention and remediation of gum and tooth decay.”\n\n• “I bought Dentist in a Bottle because my dentist told me I needed a root canal…used it twice a day, soaking the area for about two minutes. The pain and infection subsided after one day and disappeared after one week. A new dentist said that I did not need a root canal…”\n\n• “…[A]lways had problems with my teeth and gums…led to lifelong chronic gum and tooth infections . . . has completely removed the plaque buildup and now my teeth and gums feel clean and healthy…my gums have stopped bleeding. …Dentist In A Bottle”\n\nOn the “Reasons You Should Switch to a Natural Mouthwash Today” blog post, dated September 5, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Freasons-you-should-switch-to-a-natural-mouthwash-today), which contains a hyperlink to purchase Dentist In A Bottle:\n\n• “Two main ingredients in our mouthwash, Dentist in a Bottle, are Fulvic and Silver. Both are known for their antibacterial properties and can be very effective at reducing harmful bacteria. Using these two together can help prevent gum disease and tooth decay.”\n\n• “…Effective on Bacteria”\n\n• “Assistance with the prevention of tooth decay”\n\n• “Most natural rinses, like ours, contain popular ingredients like peppermint, rosemary, thyme, cinnamon bark, eucalyptus, wintergreen, lemon, clove and birch oil. Research has proven their anti bacterial [sic], antimicrobial and anti-inflammatory properties’”\n\n• “‘Oral infections can result in inflammation in other parts of the body since our oral mucosa has a direct pathway to the bloodstream.’ …Our Dentist in a Bottle offers overall improvement in oral health...”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated September 5, 2022:\n\n• “Fulvic and Silver [ingredients in Dentist In A Bottle] are known for their antibacterial properties and can be very effective at reducing harmful bacteria.”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated June 8, 2022:\n\n• “By reducing harmful bacteria growth and replacing essential mineral, Dentist in a Bottle, freshens the mouth…while assisting in the prevention and remediation of gum and tooth decay.”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated July 12, 2021:\n\n• “Our effective mouthwash is a natural alternative to toxic mouthwashes…reduces harmful bacteria growth and replaces essential minerals!”\n\nFulvic Green product\n\nOn the “The Surprising Benefits of Chlorophyll” blog post, dated August 1, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fthe-surprising-benefits-of-chlorophyll), which contains a hyperlink to purchase Fulvic Green:\n\n• Under the heading “10 Amazing Benefits of Chlorophyll” [an ingredient in Fulvic Green]:\n\n− “2. [R]epair small gut wounds.”\n\n− “5. It’s also an excellent blood purifier that helps prevent or even reverse dis-ease [sic] in your body.”\n\nOn the “Superfood Hawaiian Spirulina” blog post, dated June 27, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fsuperfood_hawaiian_spirulina), which contains a hyperlink to purchase Fulvic Green:\n\n• Under the heading “Benefits of Spirulina” [an ingredient in Fulvic Green]:\n\n− “[R]educes allergy symptoms”\n\n− “[G]reat anti-inflammation”\n\n− “[C]an reduce risk of cancer”\n\n− “[P]revents & helps with cardiovascular disease”\n\n• Under the heading “Why Take Hawaiian Spirulina [an ingredient in Fulvic Green] Supplements?”:\n\n− “Lowers Blood Pressure…A great way to lower your blood pressure is to add spirulina to your diet.”\n\n− “[S]pirulina …Foods high in antioxidants have been proven to lower inflammation and eliminate free radicals which can prevent degenerative brain diseases…spirulina helps with ADHD.”\n\n− “Lower Blood Sugar…Spirulina can lower blood sugar levels.”\n\n− “Can Reduce Risk of Cancer…Adding spirulina to your diet can reduce risk of cancer. Testing…showed the spirulina increased the production of antibodies as well as infection-fighting proteins and cells that help to protect against cancer…spirulina could have potential to prevent a number of other diseases”\n\n− “Protect Against Liver Disease…Protection against liver disease”\n\n− “Detox from Heavy Metals…Spirulina acts as a detox for your body, especially from heavy metals, like arsenic. …United States is one of the countries that are most affected by arsenic poisoning. Spirulina is a natural remedy for getting rid of that arsenic and other metals that have accumulated in the body.”\n\n− “Reduce Cholesterol…Spirulina can greatly reduce cholesterol as well. Cholesterol can be a problem that leads to heart disease…Anyone at risk for heart disease…should consider adding spirulina to their diet.”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated August 1, 2022:\n\n• Under the heading “CHLOROPHYLL [an ingredient in Fulvic Green] BENEFITS”:\n\n− “ANTI-CARCINOGENIC”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated June 27, 2022:\n\n• Under the heading “Benefits of Spirulina” [an ingredient in Fulvic Green]:\n\n− “[R]educes allergy symptoms”\n\n− “[G]reat anti-inflammation”\n\n− “[C]an reduce risk of cancer”\n\nSilver Solution product\n\nOn the Silver Solution product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fag-liquid-silver-solutions):\n\n• On the image of your product label:\n\n− [W]ide-spectrum antibacterial solution minimizes risk of infections”\n\n• “Silver [an ingredient in Silver Solution] is considered a very powerful antibacterial element because its ions cause inhibition of bacterial growth. Silver ions' interaction with enzymes and proteins play an important and essential role in antibacterial efficacy in the body.”\n\nOn the “The Many Uses of Silver” blog post, dated December 27, 2021, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fthe-many-uses-of-silver), which refers to your Silver Solution product available for purchase on your website (www.ambayagold.com):\n\n• “Taking Silver [an ingredient in Silver Solution] orally can assist with symptoms of colds, sinus infections…can lessen the symptoms of allergies and arthritis.”\n\n• “Silver [an ingredient in Silver Solution] can fight hundreds of disease causing [sic] bacteria & viruses...”\n\n• “If you don't like taking antibiotics for urinary tract or bladder infections, silver [an ingredient in Silver Solution], a natural alternative can assist to clear up your system by taking 1\u002F2 teaspoon of our Silver orally…”\n\nOn the “What's the Difference Between Silver and Gold?” blog post, dated December 13, 2021, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fwhats-the-difference-between-silver-and-gold), which refers to your Silver Solution product available for purchase on your website (www.ambayagold.com):\n\n• “Silver [an ingredient in Silver Solution] ions cause inhibition of bacterial growth. Therefore they are naturally antibacterial. Silver ions, and their interaction with enzymes and proteins play an important role in antibacterial efficacy in the body.”\n\n• “…Silver [an ingredient in Silver Solution] can be used as a non-toxic, safe, and easy to use supplement as a natural antibiotic…”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated December 19, 2021:\n\n• “Silver [an ingredient in Silver Solution] is naturally antibacterial…”\n\nDetox Cleanse Renew\n\nOn the Essentials Kit webpage (https:\u002F\u002Fambayagold.com\u002Fpages\u002Fthe-essentials-kit), which contains a hyperlink to purchase Detox Cleanse Renew:\n\n• “RESTORE FULVIC [an ingredient in Detox Cleanse Renew] RESTORE HEALTH…Toxic build up and mineral deficiencies are two of the biggest health issues that people face today and can lead to symptoms like: …Blood Sugar Imbalances…Insomnia…”\n\n• “BENEFITS OF FULVIC… REDUCES INFLAMMATION …FIGHTS PATHOGENS...”\n\nOn the “The Best Detox For Environmental Toxins And Radiation” blog post, dated July 4, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fthe_best_detox_for_environmental_toxins_and_radiation), which contains a hyperlink to purchase Detox Cleanse Renew:\n\n• “[C]ancers, disease and birth defects are increasing in both humans and animals due to environmental pollutants full of heavy metals and other toxins. …The best way to remove toxic heavy metals from environmental pollution and radiation from the body is by chelating them out with a product…Clinoptilolite Zeolite [an ingredient in Detox Cleanse Renew] is by far the best way to combat these toxins.”\n\n• “The miracle toxin magnet, Zeolite [an ingredient in Detox Cleanse Renew] …draws heavy metals and toxins to the Zeolite…enabling the toxins to be safely eliminated…”\n\n• “As the heavy metals and toxins are eliminated the immune system can grow strong again to better fight off viruses, bacteria and deformed cells...”\n\n• “Routinely detoxifying with zeolite [an ingredient in Detox Cleanse Renew] is necessary because when you’re exposed to toxins, your body stores them in your cells. Over time, toxins and radiation can build up to dangerous levels—leading to disease, chronic fatigue, brain fog and even cancer.”\n\nSilver Spray product\n\nOn the Silver Spray product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fag-liquid-silver-spray):\n\n“AMBAYA GOLD . . . SILVER SPRAY . . . wide-spectrum antibacterial solution minimizes risk of infections” [from your product label for SILVER SPRAY]\n\n“Silver Spray . . . Natural antibacterial . . . Disinfects like hydrogen peroxide without the burn . . .” [https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCmSADzUva93\u002F and https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002Fposts\u002Fpfbid02Hkd21pHbyrU5TL1MaAgRh1E9CJWtbKVenM5kyQaRtKtC4G9XL2ZMZZ58u7LApMGQl]\n\nMagnesium Oil Spray product\n\n“Our fast acting topical Magnesium Oil Spray offers the benefits of pure Magnesium Oil in a proprietary Fulvic base. . . .This convenient spray is designed is designed to provide relief from body tension and soreness quickly and effectively. . . .For muscle cramps or pains, spray directly on problem area.” [from your product website, https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fmagnesium-oil-spray]\n\nSpecifically, these products are intended for use as a first aid antiseptic, and an external analgesic, respectively1\n\nUnapproved New Drugs\n\nYour Brain Balance, Immune System Boost, Dentist In A Bottle, Essensiac, Fulvic Green, Silver Solution, and Detox Cleanse Renew products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nFurther, your “Silver Spray” product, containing silver, is a first aid antiseptic subject to section 505G of the FD&C Act, which governs nonprescription drugs marketed without an approved application. Specifically, your silver-containing product falls under section 505G(a)(5) of the FD&C Act, because FDA has determined that no silver containing OTC drugs are generally recognized as safe and effective under a final determination issued under 21 CFR part 330.2, 3 Therefore, Silver Spray is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&C Act is in effect for this drug product. Accordingly, “Silver Spray” is an unapproved new drug marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section and 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nYour “Magnesium Oil Spray” is a topical external analgesic drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to OTC external analgesic drug products, such products are deemed to be GRASE and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (“M017”).4\n\nHowever, “Magnesium Oil Spray” does not conform to the conditions specified in the final administrative order for the reasons described below. Your “Magnesium Oil Spray” is not formulated and labeled as an external analgesic counterirritant drug product that is consistent with the final administrative order. Specifically, your product is labeled to contain the ingredients magnesium chloride, fulvic, indium, aloe vera, pyridoxine HCl (B6), MSM, and plant based phytonutrients, all of which are outside of the final applicable administrative order. According to 21 CFR 201.66(b)(2), an “active ingredient” means any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans. Although your firm does not specifically list these ingredients as active ingredients, your product website includes statements that claim this combination of ingredients is “designed to provide relief from body tension and soreness” as a treatment for symptoms related to magnesium deficiency that include “leg cramps and muscle soreness,” along with “migraines, insomnia, [and] fatigue.” Such statements demonstrate that those ingredients are considered “active ingredients” as defined by 21 CFR 201.66(b)(2) because this combination of ingredients is intended to furnish pharmacological activity. However, this combination of active ingredients is not permitted under the applicable final order nor are any of these ingredients permitted as a single active ingredient in an external analgesic product under the final administrative order.\n\nThus, as formulated and labeled, “Magnesium Oil Spray” does not comply with the final administrative order described above or any applicable proposed or final rule. FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Magnesium Oil Spray” is GRASE for use under the conditions prescribed, recommended or suggested in its labeling. Moreover, there is no evident basis under the FD&C Act under which this product would be legally marketed without an approved application. Therefore, “Magnesium Oil Spray” is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Accordingly, “Magnesium Oil Spray” is an unapproved new drug marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section and 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nIn addition, “Silver Spray” and “Magnesium Oil Spray” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because they are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, are not the subject of applications approved under section 505 of the FD&C Act, 21 U.S.C. 355, and do not comply with the requirements under section 505G of the FD&C Act, 21 U.S.C. 355h. Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nMisbranded Drugs\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Brain Balance, Silver Solution, Dentist In A Bottle, Essensiac, Fulvic Green, and Detox Cleanse Renew products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, the Brain Balance, Silver Solution, Dentist In A Bottle, Essensiac, Fulvic Green, and Detox Cleanse Renew products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nUnapproved New Animal Drugs\n\nBased on our review of your website www.ambayagold.com and your social media website www.facebook.com\u002FAmbayaGoldHealth, your Pet Health+ product is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal.\n\nExamples of claims observed on your website and social media website that provide evidence that your product is intended for use as a drug include:\n\nPet Health+ product\n\nOn the Pet Health+ product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fpet-health):\n\n• “Detox of heavy metals, chemicals and other toxins* Protection from worms, parasites, and fungus* Natural anti-inflammatory agents*…Protection from infection*…Accelerated wound recovery*”\n\n• “In our Pet Health +, our clean sourced Clinoptilolite Zeolite is formulated and suspended in a freshwater Humic and Fulvic liquid solution. The Humic helps to penetrate deep into the cells, providing a cleansing action by safely binding harmful toxins.”\n\n• “Why Silver and Gold? Monatomic Silver is considered a powerful natural antibacterial element because its ions cause inhibition of bacterial growth. Silver ions' interaction with enzymes and proteins play an important and essential role in antibacterial efficacy in the body.”\n\n• A customer testimonial from 2\u002F18\u002F2022 states, “This product has help [sic] to support for our new dog’s… anxiety issues…”\n\nOn the “Natural Remedies for Pain Relief in Dogs” blog post, dated December 5, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fnatural-remedies-for-pain-relief-in-dogs), which contains a hyperlink to purchase Pet Health+:\n\n• “Holistic pet supplements and pain relievers can have a wide range of benefits like: …Assistance with detox of heavy metals, chemicals, and other toxins…Protection from worms, parasites, fungus, and infection…Natural anti-inflammatory agents…Accelerated wound recovery…All of the above benefits have been reported by users of our pet multivitamin, Pet Health+ [hyperlinks to the Pet Health+ product page].\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated May 15, 2022:\n\n• “Pet Health+ helps…Assist with detox of heavy metals, chemicals, and other toxins…Protect from worms, parasites, fungus, and infection”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated October 8, 2021, with three photos of a cat:\n\n• “…[H]er cat’s obsessive grooming…This caused her to form “hot spots” where the skin had become inflamed and formed open wounds. …When modern medicine didn’t help, she tried Pet Health+ and here are her results after ONLY a week and a half!”\n\nYour Pet Health+ product is a \"new animal drug\" under section 201(v) of the Act [21 U.S.C. § 321(v)] because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1]. Pet Health+ is not approved, conditionally approved, or index listed by the FDA, and therefore this product is considered unsafe under section 512(a) of the Act [21 U.S.C. § 360b(a)] and adulterated under section 501(a)(5) of the Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour reply should be addressed to the U.S. Food and Drug Administration; Attn: Carrie Jolly, Compliance Officer, via email at carrie.jolly@fda.hhs.gov or at 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado. You may reach Ms. Jolly at carrie.jolly@fda.hhs.gov or (303) 236-9656.\n\nSincerely,\n\n\u002FS\u002F\n\nE. Mark Harris\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations –\n\nWest Division 4\n\n_____________________\n\n1 It is not clear whether you intend your “Silver Spray” and “Magnesium Oil Spray” products to be marketed as dietary supplements. Your firm lists these two products on your website under the heading “Supplements.” Under section 201(ff)(2)(A)(i) of the FD&C Act [21 U.S.C. § 321(ff)(2)(A)(i)], a dietary supplement is defined, among other things, as a product intended for ingestion. Topical products and other products that are not intended for ingestion cannot be dietary supplements.\n\n2 See 21 CFR 310.548(b): \"Any OTC drug product containing colloidal silver ingredients or silver salts that is labeled, represented, or promoted for the treatment and\u002For prevention of any disease is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the Act) for which an approved application or abbreviated application under section 505 of the Act and part 314 of this chapter is required for marketing. In the absence of an approved new drug application or abbreviated new drug application, such product is also misbranded under section 502 of the Act.”\n\n3 FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(8)(i). Under section 505G(k)(2)(A) of the FD&C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) are deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC000007, available at OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\n\n4 Section 505G(a)(1) of the FD&C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR. part 330 prior to enactment of the CARES Act. In the case of OTC anorectal drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).","Ambaya Gold Health Products, LLC","ambaya-gold-health-products-llc-648130-12052023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fambaya-gold-health-products-llc-648130-12052023","2026-10-26T08:07:54.362384+00:00","2024-04-02","648130","Food & Beverages","Division of Human and Animal Food Operations West IV","Pilar G. Martin","2026-08-20T00:12:07.904+00:00","VIA UPS","2023-12-05",{"id":55,"raw":56,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":19,"letter_url":67,"updated_at":68,"action_type":22,"case_status":23,"posted_date":69,"marcs_cms_no":70,"product_type":71,"closeout_date":19,"issuing_office":11,"recipient_name":72,"body_fetched_at":73,"delivery_method":74,"recipient_title":19,"reference_number":19,"action_taken_date":75,"medical_device_id":19,"response_letter_date":19},21731,[57,58,59,11,60,13,13,13],"\u003Ctime datetime=\"2026-09-22T04:00:00Z\">09\u002F22\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-07-07T04:00:00Z\">07\u002F07\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fspecialty-health-products-co-llc-726564-07072026\">Specialty Health Products CO, LLC\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>John C. Kavanagh\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>QA\u002FRA Manager \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Specialty Health Products CO, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2514 E Mohawk Ln, Suite 111\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Phoenix\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85050\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 726564\u003C\u002Fp>\u003Cp>July 7, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Kavanagh:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Phoenix, AZ, from December 1, 2025, through December 11, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures and markets the Hydro-San Colonic Irrigation System (also known as Hydro-San Plus, Hydro-San, and Hydro-San Plus A Base Unit), the Aqua Cleanse Colonic Irrigation System, and Speculum Kits. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection revealed that the Hydro-San Plus, Aqua Cleanse, and Speculum Kits are adulterated under section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the Current Good Manufacturing Practice (CGMP) requirements of the Quality System (QS) Regulation found at 21 CFR Part 820. We received your firm’s responses dated January 5, 2026, February 6, 2026, March 5, 2026, April 10, 2026, May 6, 2026, and June 10, 2026. These responses are not adequate for the reasons described below.\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain design validation procedures to ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions, as required by 21 CFR 820.30(g).\u003C\u002Fp>\u003Cp>Specifically, your firm has not conducted design validation for your biocompatibility or shelf life requirements of the Class II colonic irrigation devices (Hydro-San Plus and Aqua Cleanse).\u003C\u002Fp>\u003Cp>a. Your firm does not have evidence that biocompatibility testing per ISO 10993 standards was conducted for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> material used in patient-contacting speculums despite your specifications requiring compliance to ISO 10993: Biological Evaluation of Medical Devices. Your QA\u002FRA Manager stated that no such records exist.\u003C\u002Fp>\u003Cp>b. Your firm does not have shelf-life validation studies or accelerated aging data to support the claimed 7-year shelf life for the Hydro-San Plus, despite your own risk analysis document explicitly acknowledging a 7-year shelf life due to possible deterioration of components.\u003C\u002Fp>\u003Cp>c. Your firm’s risk analysis documents are inadequate and do not address risk associated with biocompatibility of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> material. Your risk analysis documents do not reference the specific material (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), specific test reports or laboratory names, or ISO 10993 biocompatibility testing standards. Your firm’s risk analysis for the Hydro-San Plus does not evaluate risks from oxygen administration or materials incompatible with high-oxygen environments. The only documentation provided for the oxygen hose does not indicate that the tubing is rated, tested, or approved for medical oxygen delivery applications. Your firm’s risk analysis identified disinfection as a control measure but failed to ensure the control measure was adequately established. The Hydro-San Plus User Guide specifies only 15 seconds of contact time for the Cetylcide disinfectant, which is non-compliant with the manufacturer’s required 1-minute contact time for sanitizing and 10-minute contact time for virucidal activity.\u003C\u002Fp>\u003Cp>Your firm’s responses are not adequate. Your firm’s CAPA-009 response proposes reviewing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Safety Data Sheet (SDS) and conducting a single cytotoxicity test. An SDS is not a substitute for biocompatibility testing per ISO 10993 standards, and a single cytotoxicity test does not constitute adequate biocompatibility assessment for a device that contacts mucous membranes. Regarding shelf life, your firm produced a report concluding the device does not have a shelf life, which directly contradicts your own risk analysis document that stated a 7-year shelf life. Your firm has not adequately explained this discrepancy or provided evidence that components do not degrade over time. Your firm’s progress reports contain no mention of risk analysis, design validation, biocompatibility testing, or shelf-life studies.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain design change procedures as required by 21 CFR 820.30(i).\u003C\u002Fp>\u003Cp>Specifically, your firm’s Design Controls procedure (Rev B, dated 7\u002F14\u002F2023) requires design changes to be documented in Engineering Change Orders (ECOs). However, your firm could not provide ECOs or design change input approval for multiple changes to the Hydro-San Plus device, including: \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes (\u003Cstrong>(b)(4)\u003C\u002Fstrong> different valves used in various device models at unknown times with no ECO documentation); and addition of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> (implemented at an unknown point in time with no ECO or approval documentation), despite the fact that the work instruction for the Hydro-San Plus Light Unit, Document 020-0003, Rev A, dated 2\u002F5\u002F2024) demonstrates that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> strip (part \u003Cstrong>(b)(4)\u003C\u002Fstrong>) is a component of the Model A design.\u003C\u002Fp>\u003Cp>Your firm’s responses are not adequate. Your firm’s CAPA-010 response reveals a gap in understanding what constitutes a design change requiring formal control. The planned assessment of the UV light was scheduled for completion by February 27, 2026, but documentation of the assessment has not been provided. Your firm’s progress reports make no specific reference to establishing or improving design change control procedures, and your firm has not explained how it will identify all previously undocumented design changes, retrospectively review, verify, validate as appropriate, and approve those changes, or prevent future unauthorized design modifications.\u003C\u002Fp>\u003Cp>3. Failure to develop, conduct, control, and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70(a).\u003C\u002Fp>\u003Cp>Specifically,\u003C\u002Fp>\u003Cp>a. Your firm’s Aqua Cleanse Work Instruction, which documents your assembly instructions for the Aqua Cleanse device, contains no testing procedures, parameters, or acceptance criteria, and no mention of \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing procedures or duration, \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing steps or acceptable ranges, or \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing protocols.\u003C\u002Fp>\u003Cp>b. Your firm’s disinfection procedures, for the use of Cetylcide disinfectant for disinfecting colonic irrigation devices returned from the field, do not incorporate manufacturer requirements. Your firm’s disinfection procedure, Rev B, dated 6\u002F5\u002F2024 states only “Apply the Cetylcide disinfectant as instructed by the manufacturer” without incorporating specific steps for contact time requirements, dilution ratios, application methods, or verification of disinfection effectiveness.\u003C\u002Fp>\u003Cp>Your firm’s responses are not adequate. Your firm’s CAPA-017 response does not address whether current process parameters are adequate to ensure device safety and effectiveness in that in-process testing instructions are incomplete (missing test durations, steps, and parameters). Your firm’s corrective action regarding contamination control — installing a barrier around the sink while disinfecting field service returns — does not constitute proper contamination control for potentially biohazardous materials, and your firm has not addressed air handling, surface disinfection protocols, or personal protective equipment requirements. Your firm’s progress reports state only that it has “enhanced our processes and practices from receiving to customer service,” which provides no specific information about how process control procedures have been corrected.\u003C\u002Fp>\u003Cp>4. Failure to maintain complaint files and establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>Specifically,\u003C\u002Fp>\u003Cp>a. Your firm did not document formal evaluation, review, or investigation of eight complaints. RGA #411 (dated 8\u002F25\u002F2025), which involved a mislabeled speculum shipment, was closed on the same day it was opened without reference to any investigation or evaluation documentation, and no cause analysis was documented.\u003C\u002Fp>\u003Cp>b. Your firm was not consistently documenting all complaints in the RGA Log or on RGA Forms as required by your “\u003Cem>Complaint Handling, Rev. B, 6\u002F11\u002F2024\u003C\u002Fem>”. A Corrective Action Record (CAR #005, dated 1\u002F27\u002F2025) references three customer complaints from January 2025 (customers DM, AD, and SE), but no corresponding RGA numbers or RGA forms exist for these complaints.\u003C\u002Fp>\u003Cp>Your firm’s responses are not adequate. Your firm’s CAPA-008 proposes updating the complaint log and establishing formal complaint meetings but fails to address the fundamental breakdown in complaint investigation methodology. Your firm’s corrective actions focus primarily on documentation updates and form creation but do not establish clear criteria for determining when formal investigations are required, what constitutes an adequate investigation, or how to ensure complaints are properly evaluated for reportability under Medical Device Reporting (MDR) requirements. Your firm’s April 2026 progress report states only that it “started to hold formal CAPA and complaints review meetings,” but provides no evidence that the missing Complaint Report Log has been created, or that a system has been implemented to ensure complaints receive proper evaluation and investigation.\u003C\u002Fp>\u003Cp>5. Failure to establish and maintain procedures to control all documents that are required by this part, as required by 21 CFR 820.40.\u003C\u002Fp>\u003Cp>Specifically,\u003C\u002Fp>\u003Cp>a. Your firm’s current Servicing procedure (Rev B, dated 6\u002F5\u002F2024) contains no servicing steps or requirements. Instead, the body of the Environmental Controls procedure was inadvertently saved under the Servicing procedure title, and this error was not detected before the procedure was released as a controlled document.\u003C\u002Fp>\u003Cp>b. Multiple controlled documents, including the Device Master Record for the Hydro-San Plus and the Aqua Cleanse Work Instruction, were provided as editable MS Word files without password protection, electronic signatures, or any controls preventing unauthorized modification. The Aqua Cleanse work instruction was also undated and unsigned.\u003C\u002Fp>\u003Cp>Your firm’s responses are not adequate. Your firm’s CAPA-020 addresses individual instances of document control failures but does not demonstrate understanding of the systemic breakdown in your firm’s document control system. Your firm has not explained how the body of one procedure was saved under the title of another and has not addressed the need for a comprehensive overhaul of its electronic document management system, including access controls, audit trails, and version control. Your firm’s progress reports make no mention of document control improvements.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has reviewed the Specialty Health Products website, user’s guide, product catalog, and written orders, and determined that the Hydro-San Plus is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The Hydro-San Plus is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device with major changes or modifications to the intended use without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(ii).\u003C\u002Fp>\u003Cp>Specifically, the Hydro-San Colonic Irrigation System was cleared under K891585 with the following indications: The Hydro-San Colonic irrigation system is to be used when colonic irrigation is indicated. However, your firm’s promotion of the device provides evidence that the device is distributed with an intended use for colon hydrotherapy, which is an alternative practice that flushes the large intestine with warm, filtered water to remove waste typically marketed for general wellbeing, including to boost energy and detoxify the body, rather than for medical indications. This would constitute a major change or modification to its intended use, for which your firm lacks clearance or approval. Examples include:\u003C\u002Fp>\u003Cul>\u003Cli>Product catalog for the Hydro-San Plus indicates the firm Specialty Health Products is a leading manufacturer of professional colon hydro-therapy systems.\u003C\u002Fli>\u003Cli>Product webpage states the mission is to “be the premier service provider of professional Colon Hydrotherapy devices and integrated serves [sic].”\u003C\u002Fli>\u003Cli>Product webpage asserts several benefits of professional colon hydrotherapy, including improved digesting health, alleviating constipation and promoting bowel movements, lower risk of cancer, and boosting the body’s retention of vitamins and nutrients.\u003C\u002Fli>\u003Cli>Written orders indicate that the device was approved for sale for colon hydrotherapy to wellness centers.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Colonic irrigation systems are classified as Class II if the intended use is “for colon cleansing when medically indicated, such as before radiological or endoscopic examinations” per 21 CFR 876.5220(b)(1). However, per 21 CFR 876.5220(b) (2), a colonic irrigation system is classified as Class III “when the device is intended for other uses, including colon cleansing routinely for general well-being.”\u003C\u002Fp>\u003Cp>Additionally, since the Hydro-San Colonic Irrigation System was cleared under K891585, substantial technological changes were made that significantly affect the safety and effectiveness of the device. Examples include:\u003C\u002Fp>\u003Cul>\u003Cli>The Hydro-San Plus System includes the ultra-filtration collection, which are separate filtration canisters for the hot and cold-water filtration (https:\u002F\u002Fshpllc.net\u002Ffiltration\u002F). Performance and biocompatibility testing is needed to support the safety and efficacy of the filters with the system.\u003C\u002Fli>\u003Cli>The Hydro-San Plus System includes an optional Ultraviolet (UV) Light Unit. Additional performance and electrical safety testing is needed to support the safety and effectiveness of the UV Light Unit.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The distribution of colonic irrigation systems with these major changes and without the required premarket authorization may raise serious public health concerns, as colonic irrigation can lead to perforation of the rectum and\u002For colon, infection, imbalance of electrolytes, dehydration, and microbial dysbiosis.\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency, per 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed\u003C\u002Fp>\u003Cp>Our office requests that Specialty Health Products cease any activities that result in the misbranding or adulteration of the Hydro-San Plus, such as the commercial distribution of the device for the uses discussed above.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unique Device Identifier (UDI)\u002FGUDID Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The device cleared with K891585, Hydro-San Colonic Irrigation System, is misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting the device. In particular, 21 CFR 801.20(a) requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. Also, 21 CFR 830.300(a) and 830.320(b), both of which were promulgated under section 519 of the Act, among other provisions, require, with exceptions not relevant here, that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI.\u003C\u002Fp>\u003Cp>FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Specialty Health Products is therefore a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID information required by 21 CFR Part 830, subpart E, respecting this device.\u003C\u002Fp>\u003Cp>The failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\u003C\u002Fp>\u003Cp>Based on a review of the GUDID on June 30, 2026, there are no entries for Hydro-San Colonic Irrigation System under “Specialty Health Products Inc.” or under “Quality Medical Supply.”\u003C\u002Fp>\u003Cp>Your firm’s responses dated January 5, 2026, February 6, 2026, March 5, 2026, April 10, 2026, May 6, 2026, and June 10, 2026, are not adequate. Your firm’s responses do not address GUDID reporting.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Registration and Listing Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During an inspection of your firm, located in Phoenix, AZ, on December 01, 2025, through December 11, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures (or markets) the Hydro-San Colonic Irrigation System (also known as Hydro-San Plus, Hydro-San, and Hydro-San Plus A Base Unit) and the Aqua Cleanse Colonic Irrigation System. In addition to this, you also develop specifications for packaging and labeling of enema (speculum) kits to be sold with these irrigation devices. Specialty Health Products also imports enema (speculum) kits that are already packaged and labeled to distribute in the U.S.\u003C\u002Fp>\u003Cp>Your firm has registered for Fiscal Year 2026, but you have not identified your establishment as an initial importer. You also have not listed the following devices:\u003C\u002Fp>\u003Cul>\u003Cli>The modified Hydro-San Plus, using a new premarket submission number\u003C\u002Fli>\u003Cli>Aqua Cleanse enema (speculum) kits\u003C\u002Fli>\u003Cli>Hydro-San Plus enema (speculum) kits\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, the devices are misbranded in that they were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\u003C\u002Fp>\u003Cp>If you are not manufacturing and marketing the device cleared under K891585, you must deactivate that listing. Specialty Health Products must submit a new premarket submission for the Hydro-San Plus device. This device and the Hydro-San Plus enema (speculum) kits cannot be listed until the new premarket submission has been authorized. After the authorization, your firm must list the devices using the new premarket submission number. You must also list the Aqua Cleanse enema (speculum) kits using K150381.\u003C\u002Fp>\u003Cp>In addition to updating your listing information, you must also update the registration information. The owner\u002Foperator contact person must log in and change the owner\u002Foperator contact person and official correspondent’s email address and add initial importer to Specialty Health Products’ registration.\u003C\u002Fp>\u003Cp>Instructions explaining how to list exempt and non-exempt devices, update the owner\u002Foperator contact person and official correspondent information and add initial importer can be found on our website at: \u003Cu>How to Register and List | FDA\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such device will not be approved until the violations have been addressed. Should FDA determine your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a \u003Cu>final rule\u003C\u002Fu> amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The recent inspection from December 1, 2025 through December 11, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Jeffrey Wooley, Acting Assistant Director, at - CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 726564” when replying. If you have any questions about the contents of this letter, please contact Raymond Brullo at raymond.brullo@fda.hhs.gov\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>CAPT Cesar A. Perez, PhD, USPHS\u003Cbr>Acting Deputy Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJohn C. Kavanagh\n\nRecipient Title\n\nQA\u002FRA Manager\n\nSpecialty Health Products CO, LLC\n\n2514 E Mohawk Ln, Suite 111\n\nPhoenix, AZ 85050\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 726564\nJuly 7, 2026\nDear Mr. Kavanagh:\nDuring an inspection of your firm located in Phoenix, AZ, from December 1, 2025, through December 11, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures and markets the Hydro-San Colonic Irrigation System (also known as Hydro-San Plus, Hydro-San, and Hydro-San Plus A Base Unit), the Aqua Cleanse Colonic Irrigation System, and Speculum Kits. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violation(s)\nOur inspection revealed that the Hydro-San Plus, Aqua Cleanse, and Speculum Kits are adulterated under section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the Current Good Manufacturing Practice (CGMP) requirements of the Quality System (QS) Regulation found at 21 CFR Part 820. We received your firm’s responses dated January 5, 2026, February 6, 2026, March 5, 2026, April 10, 2026, May 6, 2026, and June 10, 2026. These responses are not adequate for the reasons described below.\n1. Failure to establish and maintain design validation procedures to ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions, as required by 21 CFR 820.30(g).\nSpecifically, your firm has not conducted design validation for your biocompatibility or shelf life requirements of the Class II colonic irrigation devices (Hydro-San Plus and Aqua Cleanse).\na. Your firm does not have evidence that biocompatibility testing per ISO 10993 standards was conducted for the (b)(4) material used in patient-contacting speculums despite your specifications requiring compliance to ISO 10993: Biological Evaluation of Medical Devices. Your QA\u002FRA Manager stated that no such records exist.\nb. Your firm does not have shelf-life validation studies or accelerated aging data to support the claimed 7-year shelf life for the Hydro-San Plus, despite your own risk analysis document explicitly acknowledging a 7-year shelf life due to possible deterioration of components.\nc. Your firm’s risk analysis documents are inadequate and do not address risk associated with biocompatibility of your (b)(4) material. Your risk analysis documents do not reference the specific material ((b)(4)), specific test reports or laboratory names, or ISO 10993 biocompatibility testing standards. Your firm’s risk analysis for the Hydro-San Plus does not evaluate risks from oxygen administration or materials incompatible with high-oxygen environments. The only documentation provided for the oxygen hose does not indicate that the tubing is rated, tested, or approved for medical oxygen delivery applications. Your firm’s risk analysis identified disinfection as a control measure but failed to ensure the control measure was adequately established. The Hydro-San Plus User Guide specifies only 15 seconds of contact time for the Cetylcide disinfectant, which is non-compliant with the manufacturer’s required 1-minute contact time for sanitizing and 10-minute contact time for virucidal activity.\nYour firm’s responses are not adequate. Your firm’s CAPA-009 response proposes reviewing the (b)(4) Safety Data Sheet (SDS) and conducting a single cytotoxicity test. An SDS is not a substitute for biocompatibility testing per ISO 10993 standards, and a single cytotoxicity test does not constitute adequate biocompatibility assessment for a device that contacts mucous membranes. Regarding shelf life, your firm produced a report concluding the device does not have a shelf life, which directly contradicts your own risk analysis document that stated a 7-year shelf life. Your firm has not adequately explained this discrepancy or provided evidence that components do not degrade over time. Your firm’s progress reports contain no mention of risk analysis, design validation, biocompatibility testing, or shelf-life studies.\n2. Failure to establish and maintain design change procedures as required by 21 CFR 820.30(i).\nSpecifically, your firm’s Design Controls procedure (Rev B, dated 7\u002F14\u002F2023) requires design changes to be documented in Engineering Change Orders (ECOs). However, your firm could not provide ECOs or design change input approval for multiple changes to the Hydro-San Plus device, including: (b)(4) changes ((b)(4) different valves used in various device models at unknown times with no ECO documentation); and addition of a (b)(4) (implemented at an unknown point in time with no ECO or approval documentation), despite the fact that the work instruction for the Hydro-San Plus Light Unit, Document 020-0003, Rev A, dated 2\u002F5\u002F2024) demonstrates that the (b)(4) strip (part (b)(4)) is a component of the Model A design.\nYour firm’s responses are not adequate. Your firm’s CAPA-010 response reveals a gap in understanding what constitutes a design change requiring formal control. The planned assessment of the UV light was scheduled for completion by February 27, 2026, but documentation of the assessment has not been provided. Your firm’s progress reports make no specific reference to establishing or improving design change control procedures, and your firm has not explained how it will identify all previously undocumented design changes, retrospectively review, verify, validate as appropriate, and approve those changes, or prevent future unauthorized design modifications.\n3. Failure to develop, conduct, control, and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70(a).\nSpecifically,\na. Your firm’s Aqua Cleanse Work Instruction, which documents your assembly instructions for the Aqua Cleanse device, contains no testing procedures, parameters, or acceptance criteria, and no mention of (b)(4) testing procedures or duration, (b)(4) testing steps or acceptable ranges, or (b)(4) testing protocols.\nb. Your firm’s disinfection procedures, for the use of Cetylcide disinfectant for disinfecting colonic irrigation devices returned from the field, do not incorporate manufacturer requirements. Your firm’s disinfection procedure, Rev B, dated 6\u002F5\u002F2024 states only “Apply the Cetylcide disinfectant as instructed by the manufacturer” without incorporating specific steps for contact time requirements, dilution ratios, application methods, or verification of disinfection effectiveness.\nYour firm’s responses are not adequate. Your firm’s CAPA-017 response does not address whether current process parameters are adequate to ensure device safety and effectiveness in that in-process testing instructions are incomplete (missing test durations, steps, and parameters). Your firm’s corrective action regarding contamination control — installing a barrier around the sink while disinfecting field service returns — does not constitute proper contamination control for potentially biohazardous materials, and your firm has not addressed air handling, surface disinfection protocols, or personal protective equipment requirements. Your firm’s progress reports state only that it has “enhanced our processes and practices from receiving to customer service,” which provides no specific information about how process control procedures have been corrected.\n4. Failure to maintain complaint files and establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\nSpecifically,\na. Your firm did not document formal evaluation, review, or investigation of eight complaints. RGA #411 (dated 8\u002F25\u002F2025), which involved a mislabeled speculum shipment, was closed on the same day it was opened without reference to any investigation or evaluation documentation, and no cause analysis was documented.\nb. Your firm was not consistently documenting all complaints in the RGA Log or on RGA Forms as required by your “Complaint Handling, Rev. B, 6\u002F11\u002F2024”. A Corrective Action Record (CAR #005, dated 1\u002F27\u002F2025) references three customer complaints from January 2025 (customers DM, AD, and SE), but no corresponding RGA numbers or RGA forms exist for these complaints.\nYour firm’s responses are not adequate. Your firm’s CAPA-008 proposes updating the complaint log and establishing formal complaint meetings but fails to address the fundamental breakdown in complaint investigation methodology. Your firm’s corrective actions focus primarily on documentation updates and form creation but do not establish clear criteria for determining when formal investigations are required, what constitutes an adequate investigation, or how to ensure complaints are properly evaluated for reportability under Medical Device Reporting (MDR) requirements. Your firm’s April 2026 progress report states only that it “started to hold formal CAPA and complaints review meetings,” but provides no evidence that the missing Complaint Report Log has been created, or that a system has been implemented to ensure complaints receive proper evaluation and investigation.\n5. Failure to establish and maintain procedures to control all documents that are required by this part, as required by 21 CFR 820.40.\nSpecifically,\na. Your firm’s current Servicing procedure (Rev B, dated 6\u002F5\u002F2024) contains no servicing steps or requirements. Instead, the body of the Environmental Controls procedure was inadvertently saved under the Servicing procedure title, and this error was not detected before the procedure was released as a controlled document.\nb. Multiple controlled documents, including the Device Master Record for the Hydro-San Plus and the Aqua Cleanse Work Instruction, were provided as editable MS Word files without password protection, electronic signatures, or any controls preventing unauthorized modification. The Aqua Cleanse work instruction was also undated and unsigned.\nYour firm’s responses are not adequate. Your firm’s CAPA-020 addresses individual instances of document control failures but does not demonstrate understanding of the systemic breakdown in your firm’s document control system. Your firm has not explained how the body of one procedure was saved under the title of another and has not addressed the need for a comprehensive overhaul of its electronic document management system, including access controls, audit trails, and version control. Your firm’s progress reports make no mention of document control improvements.\nUnapproved Device Violation(s)\nFDA has reviewed the Specialty Health Products website, user’s guide, product catalog, and written orders, and determined that the Hydro-San Plus is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The Hydro-San Plus is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device with major changes or modifications to the intended use without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(ii).\nSpecifically, the Hydro-San Colonic Irrigation System was cleared under K891585 with the following indications: The Hydro-San Colonic irrigation system is to be used when colonic irrigation is indicated. However, your firm’s promotion of the device provides evidence that the device is distributed with an intended use for colon hydrotherapy, which is an alternative practice that flushes the large intestine with warm, filtered water to remove waste typically marketed for general wellbeing, including to boost energy and detoxify the body, rather than for medical indications. This would constitute a major change or modification to its intended use, for which your firm lacks clearance or approval. Examples include:\nProduct catalog for the Hydro-San Plus indicates the firm Specialty Health Products is a leading manufacturer of professional colon hydro-therapy systems.\nProduct webpage states the mission is to “be the premier service provider of professional Colon Hydrotherapy devices and integrated serves [sic].”\nProduct webpage asserts several benefits of professional colon hydrotherapy, including improved digesting health, alleviating constipation and promoting bowel movements, lower risk of cancer, and boosting the body’s retention of vitamins and nutrients.\nWritten orders indicate that the device was approved for sale for colon hydrotherapy to wellness centers.\nColonic irrigation systems are classified as Class II if the intended use is “for colon cleansing when medically indicated, such as before radiological or endoscopic examinations” per 21 CFR 876.5220(b)(1). However, per 21 CFR 876.5220(b) (2), a colonic irrigation system is classified as Class III “when the device is intended for other uses, including colon cleansing routinely for general well-being.”\nAdditionally, since the Hydro-San Colonic Irrigation System was cleared under K891585, substantial technological changes were made that significantly affect the safety and effectiveness of the device. Examples include:\nThe Hydro-San Plus System includes the ultra-filtration collection, which are separate filtration canisters for the hot and cold-water filtration (https:\u002F\u002Fshpllc.net\u002Ffiltration\u002F). Performance and biocompatibility testing is needed to support the safety and efficacy of the filters with the system.\nThe Hydro-San Plus System includes an optional Ultraviolet (UV) Light Unit. Additional performance and electrical safety testing is needed to support the safety and effectiveness of the UV Light Unit.\nThe distribution of colonic irrigation systems with these major changes and without the required premarket authorization may raise serious public health concerns, as colonic irrigation can lead to perforation of the rectum and\u002For colon, infection, imbalance of electrolytes, dehydration, and microbial dysbiosis.\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency, per 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed\nOur office requests that Specialty Health Products cease any activities that result in the misbranding or adulteration of the Hydro-San Plus, such as the commercial distribution of the device for the uses discussed above.\nUnique Device Identifier (UDI)\u002FGUDID Violation\nThe device cleared with K891585, Hydro-San Colonic Irrigation System, is misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting the device. In particular, 21 CFR 801.20(a) requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. Also, 21 CFR 830.300(a) and 830.320(b), both of which were promulgated under section 519 of the Act, among other provisions, require, with exceptions not relevant here, that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI.\nFDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Specialty Health Products is therefore a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID information required by 21 CFR Part 830, subpart E, respecting this device.\nThe failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\nBased on a review of the GUDID on June 30, 2026, there are no entries for Hydro-San Colonic Irrigation System under “Specialty Health Products Inc.” or under “Quality Medical Supply.”\nYour firm’s responses dated January 5, 2026, February 6, 2026, March 5, 2026, April 10, 2026, May 6, 2026, and June 10, 2026, are not adequate. Your firm’s responses do not address GUDID reporting.\nRegistration and Listing Violation\nDuring an inspection of your firm, located in Phoenix, AZ, on December 01, 2025, through December 11, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures (or markets) the Hydro-San Colonic Irrigation System (also known as Hydro-San Plus, Hydro-San, and Hydro-San Plus A Base Unit) and the Aqua Cleanse Colonic Irrigation System. In addition to this, you also develop specifications for packaging and labeling of enema (speculum) kits to be sold with these irrigation devices. Specialty Health Products also imports enema (speculum) kits that are already packaged and labeled to distribute in the U.S.\nYour firm has registered for Fiscal Year 2026, but you have not identified your establishment as an initial importer. You also have not listed the following devices:\nThe modified Hydro-San Plus, using a new premarket submission number\nAqua Cleanse enema (speculum) kits\nHydro-San Plus enema (speculum) kits\nTherefore, the devices are misbranded in that they were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\nIf you are not manufacturing and marketing the device cleared under K891585, you must deactivate that listing. Specialty Health Products must submit a new premarket submission for the Hydro-San Plus device. This device and the Hydro-San Plus enema (speculum) kits cannot be listed until the new premarket submission has been authorized. After the authorization, your firm must list the devices using the new premarket submission number. You must also list the Aqua Cleanse enema (speculum) kits using K150381.\nIn addition to updating your listing information, you must also update the registration information. The owner\u002Foperator contact person must log in and change the owner\u002Foperator contact person and official correspondent’s email address and add initial importer to Specialty Health Products’ registration.\nInstructions explaining how to list exempt and non-exempt devices, update the owner\u002Foperator contact person and official correspondent information and add initial importer can be found on our website at: How to Register and List | FDA\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such device will not be approved until the violations have been addressed. Should FDA determine your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The recent inspection from December 1, 2025 through December 11, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Jeffrey Wooley, Acting Assistant Director, at - CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 726564” when replying. If you have any questions about the contents of this letter, please contact Raymond Brullo at raymond.brullo@fda.hhs.gov\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nCAPT Cesar A. Perez, PhD, USPHS\nActing Deputy Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Specialty Health Products CO, LLC","specialty-health-products-co-llc-726564-07072026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fspecialty-health-products-co-llc-726564-07072026","2026-11-03T01:02:17.615107+00:00","2026-09-22","726564","Medical Devices","John C. Kavanagh","2026-10-14T12:37:00.545+00:00","VIA Electronic Mail","2026-07-07",{"id":77,"raw":78,"subject":84,"body_html":85,"body_text":86,"firm_name":87,"letter_id":88,"created_at":43,"fei_number":19,"letter_url":89,"updated_at":90,"action_type":22,"case_status":23,"posted_date":91,"marcs_cms_no":92,"product_type":93,"closeout_date":19,"issuing_office":82,"recipient_name":19,"body_fetched_at":94,"delivery_method":95,"recipient_title":19,"reference_number":19,"action_taken_date":96,"medical_device_id":19,"response_letter_date":19},1721,[79,80,81,82,83,13,13,13],"\u003Ctime datetime=\"2023-11-28T14:20:00Z\">11\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-22T05:00:00Z\">11\u002F22\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdr-bernes-whole-health-products-665456-11222023\">Dr. Berne’s Whole Health Products\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug\u003Cbr \u002F>\r\n","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Dr. Berne’s Whole Health Products\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>174 Tesuque Village Rd, Unit 458\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tesuque\u003C\u002Fspan>, \u003Cspan>NM\u003C\u002Fspan> \u003Cspan>87574\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hello@drsamberne.com\"> hello@drsamberne.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 22, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 665456\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Samuel Berne:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fshop.drsamberne.com\u002F in August 2023. The FDA has observed that your website offers the products “Dr. Berne’s MSM Eye Drops 5%,” “Dr. Berne’s MSM Eye Drops 15%,” and “Dr. Berne’s MSM Eye Mist 15%” for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>Your “Dr. Berne’s MSM Eye Drops 5%,” “Dr. Berne’s MSM Eye Drops 15%,” and “Dr. Berne’s MSM Eye Mist 15%” products are especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, generally pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\u003C\u002Fp>\n\n\u003Cp>In addition, the results of the FDA laboratory testing of a batch of Dr. Berne's MSM Eye Drops 5% demonstrate that this drug product is adulterated within the meaning of section 501(a)(1) of the FD&amp;C Act, 21 U.S.C. 351(a)(1), in that it consists in whole or in part of any filthy, putrid, or decomposed substance. Introducing or delivering this product for introduction into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on a review of your website, your “Dr. Berne’s MSM Eye Drops 5%,” “Dr. Berne’s MSM Eye Drops 15%,” and “Dr. Berne’s MSM Eye Mist 15%” products are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims from your website https:\u002F\u002Fshop.drsamberne.com\u002F that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>From the Customer Sheet section on the product pages for “Dr. Berne’s MSM Eye Drops 5%” https:\u002F\u002Fshop.drsamberne.com\u002Fcollections\u002Fmsm-drops\u002Fproducts\u002Fmsm-drops, “Dr. Berne’s MSM Eye Drops 15%” https:\u002F\u002Fshop.drsamberne.com\u002Fcollections\u002Fmsm-drops\u002Fproducts\u002F15-msm, and “Dr. Berne’s MSM Eye Mist 15%” https:\u002F\u002Fshop.drsamberne.com\u002Fcollections\u002Fmsm-drops\u002Fproducts\u002Fmsm-eye-mist:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“\u003Cstrong>Allergies\u003C\u002Fstrong>[,] MSM has strong anti-inflammatory activity in the body, which can greatly assist in reducing inflammation that is common with allergic reactions. Both environmental and food allergies can be reduced with MSM. Asthma and hay fever sufferers also have reported significant relief with MSM.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your March 16, 2018, YouTube video titled, “MSM Eye Massage (Eye Exercise)” on your webpage https:\u002F\u002Fwww.drsamberne.com\u002Fmsm-eye-massage\u002F where you demonstrate an eye massage with one of your MSM eye drop products:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“This MSM eye massage is great for inflammatory eye conditions, blepharitis, dry-eye, improving the lymph system, and stimulation of tears.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your July 6, 2022, YouTube video titled, “Diagnosing Macular Degeneration” on your webpage https:\u002F\u002Fwww.drsamberne.com\u002Fdiagnosing-macular-degeneration\u002F:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“. . . I’d start using my natural eyedrops called MSM drops, and I would get the 5%, MSM and the 5% MSM. MSM is a sulfur molecule is the third leading trace mineral found in the body. And it supports collagen in the eye. It’s an anti inflammatory agent. And it will lubricate and moisturize your eyes, which neutralizes drusen production because drusen likes to grow in a dry environment. And the other thing it will do is it will lubricate your macula. So when you’ve got dry macular degeneration, the macula is basically drying out. And that’s where you start getting these distortions.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your October 12, 2022, YouTube video titled, “I’m Answering Your Questions! Sulfa vs. Sulfur” on your webpage https:\u002F\u002Fwww.drsamberne.com\u002Fim-answering-your-questions-sulfa-vs-sulfur\u002F:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“[T]he difference between those two pharmaceuticals and MSM eyedrops, so MSM definitely is an anti inflammatory agent. It’s a natural sulfur product that is found in your body.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your October 31, 2022, YouTube video titled, “I’m Answering Your Questions” on your webpage https:\u002F\u002Fwww.drsamberne.com\u002Fim-answering-your-questions-12\u002F:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“My MSM eyedrops are really great for corneal dystrophies, like fuks, and it’s really about hydrating, protecting your eyes from too much sunlight, and also blue light . . .”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your “Dr. Berne’s MSM Eye Drops 5%,” “Dr. Berne’s MSM Eye Drops 15%,” and “Dr. Berne’s MSM Eye Mist 15%” products are not generally recognized as safe and effective (GRASE) for their above-referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA laboratory testing of a batch of Dr. Berne's MSM DROPS 5% Solution drug product (lot 6786, “Best By 032025”) found that it contained microbial contamination. The sample results failed to meet USP &lt;71&gt;, sterility tests. Therefore, this drug product is adulterated under section 501(a)(1) of the FD&amp;C Act, in that it consists in whole or in part of any filthy, putrid, or decomposed substances.\u003C\u002Fp>\n\n\u003Cp>Fungal and bacterial microorganisms were identified from drug product samples analyzed for sterility, which included, but were not limited to Exophiala sp. and Bacillus spp. The presence of microorganisms in conjunction with the route of administration poses a high risk to patients. Using contaminated eye drops could result in a range of ocular infections, from minor to serious vision-threatening infections, which could progress in some cases to a life-threatening infection.\u003C\u002Fp>\n\n\u003Cp>During the FDA teleconference on August 21, 2023, you stated that your drug products are manufactured by a contract manufacturer, and you agreed to conduct a voluntary recall of the lot currently in U.S. distribution.\u003C\u002Fp>\n\n\u003Cp>On August 26, 2023, you voluntarily recalled lot 6786 of Dr. Berne’s MSM DROPS 5% Solution to the consumer level due to microbial contamination. In addition, you are voluntarily recalling all lots of Dr. Berne’s MSM DROPS 5% Solution, Dr. Berne’s MSM DROPS 15% Solution, Dr. Berne’s Organic Castor Oil Eye Drops, and Dr. Berne’s MSM MIST 15% Solution to the consumer level due to potential microbial contamination, as noted on the following FDA website:\u003Cbr>\nhttps:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fdr-bernes-whole-health-products-issues-voluntary-nationwide-recall-dr-bernes-msm-drops-5-and-15\u003C\u002Fp>\n\n\u003Cp>On August 22, 2023, FDA issued the following drug alert warning to consumers not to purchase and to immediately stop using Dr. Berne’s MSM Drops 5% Solution due to bacterial contamination, fungal contamination, or both:\u003Cbr>\nhttps:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-warns-consumers-not-purchase-or-use-certain-methylsulfonylmethane-msm-eye-drops-due\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Use of Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003Cbr>\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act. For additional information regarding contract manufacturing, please refer to FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003Cbr>\n\u003Cbr>\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address any violations may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jill Furman\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nDr. Berne’s Whole Health Products\n\n174 Tesuque Village Rd, Unit 458\n\nTesuque, NM 87574\n\nUnited States\n\nhello@drsamberne.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nNovember 22, 2023\n\nRE: 665456\n\nDear Samuel Berne:\n\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fshop.drsamberne.com\u002F in August 2023. The FDA has observed that your website offers the products “Dr. Berne’s MSM Eye Drops 5%,” “Dr. Berne’s MSM Eye Drops 15%,” and “Dr. Berne’s MSM Eye Mist 15%” for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nYour “Dr. Berne’s MSM Eye Drops 5%,” “Dr. Berne’s MSM Eye Drops 15%,” and “Dr. Berne’s MSM Eye Mist 15%” products are especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, generally pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\n\nIn addition, the results of the FDA laboratory testing of a batch of Dr. Berne's MSM Eye Drops 5% demonstrate that this drug product is adulterated within the meaning of section 501(a)(1) of the FD&C Act, 21 U.S.C. 351(a)(1), in that it consists in whole or in part of any filthy, putrid, or decomposed substance. Introducing or delivering this product for introduction into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nUnapproved New Drugs\n\nBased on a review of your website, your “Dr. Berne’s MSM Eye Drops 5%,” “Dr. Berne’s MSM Eye Drops 15%,” and “Dr. Berne’s MSM Eye Mist 15%” products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims from your website https:\u002F\u002Fshop.drsamberne.com\u002F that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\n\nFrom the Customer Sheet section on the product pages for “Dr. Berne’s MSM Eye Drops 5%” https:\u002F\u002Fshop.drsamberne.com\u002Fcollections\u002Fmsm-drops\u002Fproducts\u002Fmsm-drops, “Dr. Berne’s MSM Eye Drops 15%” https:\u002F\u002Fshop.drsamberne.com\u002Fcollections\u002Fmsm-drops\u002Fproducts\u002F15-msm, and “Dr. Berne’s MSM Eye Mist 15%” https:\u002F\u002Fshop.drsamberne.com\u002Fcollections\u002Fmsm-drops\u002Fproducts\u002Fmsm-eye-mist:\n\n“Allergies[,] MSM has strong anti-inflammatory activity in the body, which can greatly assist in reducing inflammation that is common with allergic reactions. Both environmental and food allergies can be reduced with MSM. Asthma and hay fever sufferers also have reported significant relief with MSM.”\n\nFrom your March 16, 2018, YouTube video titled, “MSM Eye Massage (Eye Exercise)” on your webpage https:\u002F\u002Fwww.drsamberne.com\u002Fmsm-eye-massage\u002F where you demonstrate an eye massage with one of your MSM eye drop products:\n\n“This MSM eye massage is great for inflammatory eye conditions, blepharitis, dry-eye, improving the lymph system, and stimulation of tears.”\n\nFrom your July 6, 2022, YouTube video titled, “Diagnosing Macular Degeneration” on your webpage https:\u002F\u002Fwww.drsamberne.com\u002Fdiagnosing-macular-degeneration\u002F:\n\n“. . . I’d start using my natural eyedrops called MSM drops, and I would get the 5%, MSM and the 5% MSM. MSM is a sulfur molecule is the third leading trace mineral found in the body. And it supports collagen in the eye. It’s an anti inflammatory agent. And it will lubricate and moisturize your eyes, which neutralizes drusen production because drusen likes to grow in a dry environment. And the other thing it will do is it will lubricate your macula. So when you’ve got dry macular degeneration, the macula is basically drying out. And that’s where you start getting these distortions.”\n\nFrom your October 12, 2022, YouTube video titled, “I’m Answering Your Questions! Sulfa vs. Sulfur” on your webpage https:\u002F\u002Fwww.drsamberne.com\u002Fim-answering-your-questions-sulfa-vs-sulfur\u002F:\n\n“[T]he difference between those two pharmaceuticals and MSM eyedrops, so MSM definitely is an anti inflammatory agent. It’s a natural sulfur product that is found in your body.”\n\nFrom your October 31, 2022, YouTube video titled, “I’m Answering Your Questions” on your webpage https:\u002F\u002Fwww.drsamberne.com\u002Fim-answering-your-questions-12\u002F:\n\n“My MSM eyedrops are really great for corneal dystrophies, like fuks, and it’s really about hydrating, protecting your eyes from too much sunlight, and also blue light . . .”\n\nYour “Dr. Berne’s MSM Eye Drops 5%,” “Dr. Berne’s MSM Eye Drops 15%,” and “Dr. Berne’s MSM Eye Mist 15%” products are not generally recognized as safe and effective (GRASE) for their above-referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nAdulteration Violations\n\nFDA laboratory testing of a batch of Dr. Berne's MSM DROPS 5% Solution drug product (lot 6786, “Best By 032025”) found that it contained microbial contamination. The sample results failed to meet USP \u003C71>, sterility tests. Therefore, this drug product is adulterated under section 501(a)(1) of the FD&C Act, in that it consists in whole or in part of any filthy, putrid, or decomposed substances.\n\nFungal and bacterial microorganisms were identified from drug product samples analyzed for sterility, which included, but were not limited to Exophiala sp. and Bacillus spp. The presence of microorganisms in conjunction with the route of administration poses a high risk to patients. Using contaminated eye drops could result in a range of ocular infections, from minor to serious vision-threatening infections, which could progress in some cases to a life-threatening infection.\n\nDuring the FDA teleconference on August 21, 2023, you stated that your drug products are manufactured by a contract manufacturer, and you agreed to conduct a voluntary recall of the lot currently in U.S. distribution.\n\nOn August 26, 2023, you voluntarily recalled lot 6786 of Dr. Berne’s MSM DROPS 5% Solution to the consumer level due to microbial contamination. In addition, you are voluntarily recalling all lots of Dr. Berne’s MSM DROPS 5% Solution, Dr. Berne’s MSM DROPS 15% Solution, Dr. Berne’s Organic Castor Oil Eye Drops, and Dr. Berne’s MSM MIST 15% Solution to the consumer level due to potential microbial contamination, as noted on the following FDA website:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fdr-bernes-whole-health-products-issues-voluntary-nationwide-recall-dr-bernes-msm-drops-5-and-15\n\nOn August 22, 2023, FDA issued the following drug alert warning to consumers not to purchase and to immediately stop using Dr. Berne’s MSM Drops 5% Solution due to bacterial contamination, fungal contamination, or both:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-warns-consumers-not-purchase-or-use-certain-methylsulfonylmethane-msm-eye-drops-due\n\nUse of Contract Manufacturers\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act. For additional information regarding contract manufacturing, please refer to FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address any violations may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Furman\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration","Dr. Berne’s Whole Health Products","dr-bernes-whole-health-products-665456-11222023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdr-bernes-whole-health-products-665456-11222023","2026-10-26T08:08:26.526839+00:00","2023-11-28","665456","Drugs","2026-08-20T00:28:51.97+00:00","Via Email","2023-11-22",{"id":98,"raw":99,"subject":104,"body_html":106,"body_text":107,"firm_name":108,"letter_id":109,"created_at":110,"fei_number":19,"letter_url":111,"updated_at":112,"action_type":22,"case_status":113,"posted_date":114,"marcs_cms_no":115,"product_type":48,"closeout_date":116,"issuing_office":103,"recipient_name":117,"body_fetched_at":118,"delivery_method":119,"recipient_title":19,"reference_number":19,"action_taken_date":120,"medical_device_id":19,"response_letter_date":19},1231,[100,101,102,103,104,13,105,13],"\u003Ctime datetime=\"2024-10-01T13:20:00Z\">10\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-11T04:00:00Z\">09\u002F11\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealthwest-minerals-inc-dba-mt-capra-products-685115-09112024\">Healthwest Minerals, Inc. dba Mt. Capra Products\u003C\u002Fa>","Division of Human and Animal Food Operations West VI","Interstate Commerce\u002FFood\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealthwest-minerals-inc-dba-mt-capra-products-685115-09032025\">\u003Ctime datetime=\"2025-09-08T04:00:00Z\">09\u002F08\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joseph C. Stout\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Healthwest Minerals, Inc. dba Mt. Capra Products\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>279 Southwest 9th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chehalis\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98532-3313\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations West VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 11, 2024\u003C\u002Fp>\n\n\u003Cp>In reply, refer to CMS 685115\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AMENDED WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Stout:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address, https:\u002F\u002Fmtcapra.com and your social media website at https:\u002F\u002Fwww.facebook.com\u002Fmtcapra in March and April 2024. Based on representations made on your websites at the time we reviewed them, your Goat Milk Formula Recipe Kit met the definition of an infant formula under section 201(z) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(z)] because it was a food which purported to be or was represented for special dietary use solely as a food for infants by reason of its simulation of human milk or its suitability as a complete or partial substitute for human milk. For example:\u003C\u002Fp>\n\n\u003Cp>• On your websites at https:\u002F\u002Fmtcapra.com\u002Fcategory\u002Fgoat-milk-formula\u002F:\u003C\u002Fp>\n\n\u003Cp>o “We have created a formula recipe that mimics breast milk and follows the guidelines created by the 1980 Infant Formula Act.”\u003C\u002Fp>\n\n\u003Cp>• On your website at https:\u002F\u002Fmtcapra.com\u002Fproduct\u002Fhomemade-goat-milk-formula-kit:\u003C\u002Fp>\n\n\u003Cp>o “The all-natural preferred alternative to commercial baby formula. This Goat Milk Recipe Kit supplies you with all of the wholesome, REAL FOOD ingredients your little one needs to thrive.”\u003C\u002Fp>\n\n\u003Cp>o “This goat milk formula recipe kit contains all the ingredients you need to get started making your own goat milk formula at home! The kit will produce 256 oz of formula before you need to purchase more milk and lactose. Some of the ingredients in the kit will last much longer. Note: This recipe kit is not a finished, ready-to-mix, infant formula but rather a combination of different REAL FOODS for those who cannot or choose not to breastfeed. If breastfeeding is not an option, this kit could be the answer you’ve been searching for: the perfect DIY alternative to commercial infant formula.”\u003C\u002Fp>\n\n\u003Cp>• On your Facebook page at https:\u002F\u002Fwww.facebook.com\u002Fmtcapra:\u003C\u002Fp>\n\n\u003Cp>o Your February 12, 2024, post: “‘Infant formula is the number one regulated food in the U.S., and yet the allowable ingredients in off-the-shelf infant formula is often times very very poor. So there is a very good incentive to make your own formula.’ Get to know the creator, Joe Stout, and learn about the Goat Milk Formula Recipe on the GMF Livestream replay! . . . #DIYBabyFormula . . .”\u003C\u002Fp>\n\n\u003Cp>o Your October 18, 2023, post: “Our Goat Milk Formula was created nearly 10 years ago by our company President, Joe Stout. His newborn daughter, Liesl, was struggling with commercial formula. Since then, they have used the formula recipe with several of their 9 children, and provided a healthy solution for countless little ones and their parents. Swipe through to learn why our Goat Milk Formula is a standout. . . . Not only is goat milk the perfect substitute for cow milk, but its DNA is very similar to breast milk.”\u003C\u002Fp>\n\n\u003Cp>At the time we reviewed your websites, your Goat Milk Formula Recipe Kit product was a new infant formula under section 412(c)(2)(A) of the Act [21 U.S.C. § 350a(c)(2)(A)] because you had not previously manufactured an infant formula. See also 21 CFR 106.3 (defining “new infant formula,” in part, as a formula “which has not previously been the subject of a submission under section 412(c)” of the Act). A person who introduces a new infant formula into interstate commerce must make a submission that complies with section 412(d)(1) of the Act [21 U.S.C. § 350a(d)(1)].\u003C\u002Fp>\n\n\u003Cp>Under section 412(c)(1)(B) of the Act [21 U.S.C. § 350a(c)(1)(B)], no person shall introduce or deliver for introduction into interstate commerce a new infant formula unless such person has at least 90 days prior to marketing the new infant formula, made the submission required by section 412(d)(1). The failure to make such a submission at least 90 days prior to marketing a new infant formula is a violation of section 412(c)(1)(B) of the Act [21 U.S.C. § 350a(c)(1)(B)] and this is a prohibited act under section 301(s) of the Act [21 U.S.C. § 331(s)]. You may find the Act and FDA’s regulations through links in FDA’s home page at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that after a teleconference with you on May 7, 2024, you voluntarily recalled all Goat Milk Formula Recipe Kit product distributed between May 1, 2023, and May 1, 2024. We are aware that you contacted all customers who received product during that timeframe to inform them that the product should not be used as an infant formula. Additionally, you issued a press release on May 10, 2024, clarifying to the general public that you do not recommend using this product for infants from 0-12 months of age. We also acknowledge that you removed the ability to purchase the Goat Milk Formula Recipe Kit from your website, and that you made some changes to your website and social media websites, including but not limited to removing the above-mentioned statements regarding use as an infant formula. However, due to the serious public health concerns related to your unlawful marketing of a new infant formula, it is essential that this violation does not recur.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to prevent the recurrence of future violations. If you believe that your products were not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, 22215 26th Avenue SE, Suite 210, Bothell, Washington, 98021-4421, to the attention of Tracy K. Li, Compliance Officer. If you have any questions concerning this letter, you can contact Tracy K. Li at (425) 302-0428, or by email at Tracy.Li@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Miriam R. Burbach\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations West – Division 6\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nOvernight Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJoseph C. Stout\n\nRecipient Title\n\nPresident\n\nHealthwest Minerals, Inc. dba Mt. Capra Products\n\n279 Southwest 9th Street\n\nChehalis, WA 98532-3313\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West VI\n\nUnited States\n\nSeptember 11, 2024\n\nIn reply, refer to CMS 685115\n\nAMENDED WARNING LETTER\n\nDear Mr. Stout:\n\nThe U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address, https:\u002F\u002Fmtcapra.com and your social media website at https:\u002F\u002Fwww.facebook.com\u002Fmtcapra in March and April 2024. Based on representations made on your websites at the time we reviewed them, your Goat Milk Formula Recipe Kit met the definition of an infant formula under section 201(z) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(z)] because it was a food which purported to be or was represented for special dietary use solely as a food for infants by reason of its simulation of human milk or its suitability as a complete or partial substitute for human milk. For example:\n\n• On your websites at https:\u002F\u002Fmtcapra.com\u002Fcategory\u002Fgoat-milk-formula\u002F:\n\no “We have created a formula recipe that mimics breast milk and follows the guidelines created by the 1980 Infant Formula Act.”\n\n• On your website at https:\u002F\u002Fmtcapra.com\u002Fproduct\u002Fhomemade-goat-milk-formula-kit:\n\no “The all-natural preferred alternative to commercial baby formula. This Goat Milk Recipe Kit supplies you with all of the wholesome, REAL FOOD ingredients your little one needs to thrive.”\n\no “This goat milk formula recipe kit contains all the ingredients you need to get started making your own goat milk formula at home! The kit will produce 256 oz of formula before you need to purchase more milk and lactose. Some of the ingredients in the kit will last much longer. Note: This recipe kit is not a finished, ready-to-mix, infant formula but rather a combination of different REAL FOODS for those who cannot or choose not to breastfeed. If breastfeeding is not an option, this kit could be the answer you’ve been searching for: the perfect DIY alternative to commercial infant formula.”\n\n• On your Facebook page at https:\u002F\u002Fwww.facebook.com\u002Fmtcapra:\n\no Your February 12, 2024, post: “‘Infant formula is the number one regulated food in the U.S., and yet the allowable ingredients in off-the-shelf infant formula is often times very very poor. So there is a very good incentive to make your own formula.’ Get to know the creator, Joe Stout, and learn about the Goat Milk Formula Recipe on the GMF Livestream replay! . . . #DIYBabyFormula . . .”\n\no Your October 18, 2023, post: “Our Goat Milk Formula was created nearly 10 years ago by our company President, Joe Stout. His newborn daughter, Liesl, was struggling with commercial formula. Since then, they have used the formula recipe with several of their 9 children, and provided a healthy solution for countless little ones and their parents. Swipe through to learn why our Goat Milk Formula is a standout. . . . Not only is goat milk the perfect substitute for cow milk, but its DNA is very similar to breast milk.”\n\nAt the time we reviewed your websites, your Goat Milk Formula Recipe Kit product was a new infant formula under section 412(c)(2)(A) of the Act [21 U.S.C. § 350a(c)(2)(A)] because you had not previously manufactured an infant formula. See also 21 CFR 106.3 (defining “new infant formula,” in part, as a formula “which has not previously been the subject of a submission under section 412(c)” of the Act). A person who introduces a new infant formula into interstate commerce must make a submission that complies with section 412(d)(1) of the Act [21 U.S.C. § 350a(d)(1)].\n\nUnder section 412(c)(1)(B) of the Act [21 U.S.C. § 350a(c)(1)(B)], no person shall introduce or deliver for introduction into interstate commerce a new infant formula unless such person has at least 90 days prior to marketing the new infant formula, made the submission required by section 412(d)(1). The failure to make such a submission at least 90 days prior to marketing a new infant formula is a violation of section 412(c)(1)(B) of the Act [21 U.S.C. § 350a(c)(1)(B)] and this is a prohibited act under section 301(s) of the Act [21 U.S.C. § 331(s)]. You may find the Act and FDA’s regulations through links in FDA’s home page at http:\u002F\u002Fwww.fda.gov.\n\nWe acknowledge that after a teleconference with you on May 7, 2024, you voluntarily recalled all Goat Milk Formula Recipe Kit product distributed between May 1, 2023, and May 1, 2024. We are aware that you contacted all customers who received product during that timeframe to inform them that the product should not be used as an infant formula. Additionally, you issued a press release on May 10, 2024, clarifying to the general public that you do not recommend using this product for infants from 0-12 months of age. We also acknowledge that you removed the ability to purchase the Goat Milk Formula Recipe Kit from your website, and that you made some changes to your website and social media websites, including but not limited to removing the above-mentioned statements regarding use as an infant formula. However, due to the serious public health concerns related to your unlawful marketing of a new infant formula, it is essential that this violation does not recur.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to prevent the recurrence of future violations. If you believe that your products were not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the Food and Drug Administration, 22215 26th Avenue SE, Suite 210, Bothell, Washington, 98021-4421, to the attention of Tracy K. Li, Compliance Officer. If you have any questions concerning this letter, you can contact Tracy K. Li at (425) 302-0428, or by email at Tracy.Li@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMiriam R. Burbach\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations West – Division 6","Healthwest Minerals, Inc. dba Mt. Capra Products","healthwest-minerals-inc-dba-mt-capra-products-685115-09112024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealthwest-minerals-inc-dba-mt-capra-products-685115-09112024","2026-10-26T08:08:53.840094+00:00","Closed Out","2024-10-01","685115","2025-09-08","Joseph C. Stout","2026-08-19T22:57:24.092+00:00","Overnight Delivery","2024-09-11",{"id":122,"raw":123,"subject":127,"body_html":128,"body_text":129,"firm_name":130,"letter_id":131,"created_at":132,"fei_number":19,"letter_url":133,"updated_at":134,"action_type":22,"case_status":23,"posted_date":135,"marcs_cms_no":136,"product_type":93,"closeout_date":19,"issuing_office":82,"recipient_name":137,"body_fetched_at":138,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":139,"medical_device_id":19,"response_letter_date":19},2731,[124,125,126,82,127,13,13,13],"\u003Ctime datetime=\"2022-04-19T13:20:00Z\">04\u002F19\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-04-13T04:00:00Z\">04\u002F13\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrue-earth-health-products-llc-628383-04132022\">True Earth Health Products, LLC\u003C\u002Fa>","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jonathan Greenhut\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>True Earth Health Products, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>260 Smith St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Farmingdale\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11735\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:CustomerCare@SheerScience.com\"> CustomerCare@SheerScience.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: April 13, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Greenhut,\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s distribution of a drug product to bleach and\u002For lighten the skin. Plexaderm® Skincare DARK SPOT FADE GEL drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Plexaderm® Skincare DARK SPOT FADE GEL is a drug as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a skin bleaching product.\u003C\u002Fp>\n\n\u003Cp>Examples of the claims observed on your product label and labeling from your website Sheerscience.com, where the product is available for purchase, that provide evidence of the intended use (as defined in 21 CFR 201.128) of your product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>Dark Spot Fade Gel\u003C\u002Fstrong> is the ultimate skin brightening treatment for hyperpigmentation, skin discoloration and age spots. . . . \u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . \u003Cstrong>Active Ingredients\u003C\u002Fstrong> Hydroquinone 2% . . . \u003Cstrong>Purpose\u003C\u002Fstrong> . . . Skin Lightener . . . \u003Cstrong>Uses\u003C\u002Fstrong> For the gradual fading of ■ dark spots ■ freckles ■ age spots ■ brownish skin discolorations” [from your Plexaderm® Skincare DARK SPOT FADE GEL label]\u003C\u002Fp>\n\n\u003Cp>“Dark Spot Fade Gel is the ultimate skin brightening treatment for hyperpigmentation, skin discoloration, and age spots. It combines the proven benefits of Hydroquinone with a powerful blend of emollients, exfoliating and brightening ingredients to reveal a visibly softer, smoother, more balanced complexion. . . . This product will help balance uneven skin tone from sun damage, age spots, and hyperpigmentation that have formed on the skin’s surface over the years.” [from your website https:\u002F\u002Fwww.sheerscience.com\u002Fskincare\u002F]\u003C\u002Fp>\n\n\u003Cp>Plexaderm® Skincare DARK SPOT FADE GEL is a skin bleaching drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these skin bleaching products fall under section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), as added on March 27, 2020 with the enactment of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), because they are subject to a determination to be not generally recognized as safe and effective (GRASE) in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Thus, Plexaderm® Skincare DARK SPOT FADE GEL is deemed to be a new drug under section 201(p)(1) of the FD&amp;C Act and subject to the requirement to have an approved new drug application for marketing under section 505 of the FD&amp;C Act, 21 U.S.C. 355, beginning on September 23, 2020.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for Plexaderm® Skincare DARK SPOT FADE GEL. Accordingly, this skin bleaching drug product is an unapproved new drug and its introduction or delivery for introduction into interstate commerce violates section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>Moreover, Plexaderm® Skincare DARK SPOT FADE GEL is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because it is deemed as such under section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), and because it is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355, and does not comply with the requirements under section 505G of the FD&amp;C Act, 21 U.S.C. 355h. The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations regarding your products nor is the skin bleaching\u002Fskin lightening drug product named in this letter intended to be an all-inclusive list of products you have manufactured, registered, and\u002For listed in FDA’s electronic drug registration and listing system (eDRLS), or introduced into interstate commerce. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence and the occurrence of other violations. It is your responsibility to assure that your firm complies with all requirements of federal law and FDA regulations. You should take prompt action to correct the violations cited in this letter. Failure to promptly correct any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations of the FD&amp;C Act may be cause for FDA to withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address violations within 15 working days, state your reasons for delay and schedule for completion.\u003C\u002Fp>\n\n\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct your email response to Office of Unapproved Drugs and Labeling Compliance at the following email address to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Carolyn E. Becker\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On August 29, 2006 FDA issued a proposed rule (71 FR 51146) setting forth a determination that OTC skin bleaching drug products, including but not limited to those that contain hydroquinone as an active ingredient, are not generally recognized as safe and effective.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), authorized FDA to take action before September 23, 2020 to extend the period during which a drug subject to that section may be marketed without an approved new drug application if the Agency determined that such an extension is in the interest of public health. However, FDA did not make such a determination for skin bleaching products.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJonathan Greenhut\n\nRecipient Title\n\nChief Executive Officer\n\nTrue Earth Health Products, LLC\n\n260 Smith St\n\nFarmingdale, NY 11735\n\nUnited States\n\nCustomerCare@SheerScience.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nDate: April 13, 2022\n\nDear Mr. Greenhut,\n\nThis letter concerns your firm’s distribution of a drug product to bleach and\u002For lighten the skin. Plexaderm® Skincare DARK SPOT FADE GEL drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nUnapproved New Drug and Misbranded Drug Violations\n\nPlexaderm® Skincare DARK SPOT FADE GEL is a drug as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a skin bleaching product.\n\nExamples of the claims observed on your product label and labeling from your website Sheerscience.com, where the product is available for purchase, that provide evidence of the intended use (as defined in 21 CFR 201.128) of your product include, but may not be limited to, the following:\n\n“Dark Spot Fade Gel is the ultimate skin brightening treatment for hyperpigmentation, skin discoloration and age spots. . . . Drug Facts . . . Active Ingredients Hydroquinone 2% . . . Purpose . . . Skin Lightener . . . Uses For the gradual fading of ■ dark spots ■ freckles ■ age spots ■ brownish skin discolorations” [from your Plexaderm® Skincare DARK SPOT FADE GEL label]\n\n“Dark Spot Fade Gel is the ultimate skin brightening treatment for hyperpigmentation, skin discoloration, and age spots. It combines the proven benefits of Hydroquinone with a powerful blend of emollients, exfoliating and brightening ingredients to reveal a visibly softer, smoother, more balanced complexion. . . . This product will help balance uneven skin tone from sun damage, age spots, and hyperpigmentation that have formed on the skin’s surface over the years.” [from your website https:\u002F\u002Fwww.sheerscience.com\u002Fskincare\u002F]\n\nPlexaderm® Skincare DARK SPOT FADE GEL is a skin bleaching drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these skin bleaching products fall under section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), as added on March 27, 2020 with the enactment of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), because they are subject to a determination to be not generally recognized as safe and effective (GRASE) in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330.1 Thus, Plexaderm® Skincare DARK SPOT FADE GEL is deemed to be a new drug under section 201(p)(1) of the FD&C Act and subject to the requirement to have an approved new drug application for marketing under section 505 of the FD&C Act, 21 U.S.C. 355, beginning on September 23, 2020.2\n\nNo FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for Plexaderm® Skincare DARK SPOT FADE GEL. Accordingly, this skin bleaching drug product is an unapproved new drug and its introduction or delivery for introduction into interstate commerce violates section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nMoreover, Plexaderm® Skincare DARK SPOT FADE GEL is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because it is deemed as such under section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), and because it is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355, and does not comply with the requirements under section 505G of the FD&C Act, 21 U.S.C. 355h. The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations regarding your products nor is the skin bleaching\u002Fskin lightening drug product named in this letter intended to be an all-inclusive list of products you have manufactured, registered, and\u002For listed in FDA’s electronic drug registration and listing system (eDRLS), or introduced into interstate commerce. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence and the occurrence of other violations. It is your responsibility to assure that your firm complies with all requirements of federal law and FDA regulations. You should take prompt action to correct the violations cited in this letter. Failure to promptly correct any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nFailure to address violations of the FD&C Act may be cause for FDA to withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address violations within 15 working days, state your reasons for delay and schedule for completion.\n\nIf you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct your email response to Office of Unapproved Drugs and Labeling Compliance at the following email address to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nCarolyn E. Becker\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n________________________\n\n1 On August 29, 2006 FDA issued a proposed rule (71 FR 51146) setting forth a determination that OTC skin bleaching drug products, including but not limited to those that contain hydroquinone as an active ingredient, are not generally recognized as safe and effective.\n\n2 Section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), authorized FDA to take action before September 23, 2020 to extend the period during which a drug subject to that section may be marketed without an approved new drug application if the Agency determined that such an extension is in the interest of public health. However, FDA did not make such a determination for skin bleaching products.","True Earth Health Products, LLC","true-earth-health-products-llc-628383-04132022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrue-earth-health-products-llc-628383-04132022","2026-10-26T08:10:15.522721+00:00","2022-04-19","628383","Jonathan Greenhut","2026-08-20T02:00:24.289+00:00","2022-04-13",{"id":141,"raw":142,"subject":147,"body_html":148,"body_text":149,"firm_name":150,"letter_id":151,"created_at":152,"fei_number":19,"letter_url":153,"updated_at":154,"action_type":22,"case_status":23,"posted_date":155,"marcs_cms_no":156,"product_type":157,"closeout_date":19,"issuing_office":146,"recipient_name":158,"body_fetched_at":159,"delivery_method":95,"recipient_title":19,"reference_number":19,"action_taken_date":160,"medical_device_id":19,"response_letter_date":19},177,[143,144,145,146,147,13,13,13],"\u003Ctime datetime=\"2026-05-12T04:00:00Z\">05\u002F12\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-29T04:00:00Z\">04\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Foptihealth-products-inc-704899-04292026\">OptiHealth Products, Inc.\u003C\u002Fa>","Human Foods Program","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Russell Dickson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>OptiHealth Products, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>275 River Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint James\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11780\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@optihealthstore.com\"> support@optihealthstore.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 29, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS # 704899\u003C\u002Fp>\u003Cp>Dear Mr. Dickson:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Foptihealthproducts.com in December 2025 and has determined that you take orders there for your product Super Antioxidant (OPCXtra). We also reviewed your social media website at https:\u002F\u002Fwww.facebook.com\u002FOptiHealthProducts where you direct consumers to your website,\u003Cbr>https:\u002F\u002Foptihealthproducts.com\u002F to purchase your products. The claims on your website, https:\u002F\u002Foptihealthproducts.com\u002F establish that this product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\u003Cp>Examples of some of the claims that provide evidence that your product is intended for use as a drug include:\u003C\u002Fp>\u003Cp>“\u003Cstrong>6 Remarkable Benefits of Bilberry Extract\u003C\u002Fstrong>\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>” https:\u002F\u002Foptihealthproducts.com\u002Fblogs\u002Fnews\u002F6-remarkable-benefits-of-bilberry-extract\u003C\u002Fp>\u003Cul>\u003Cli>Under the section, \u003Cstrong>“Heart Health Support”\u003C\u002Fstrong>\u003Cbr>o “The antioxidants in bilberries are believed to help reduce the risk of heart disease by improving blood vessel function, reducing blood pressure, and lowering cholesterol levels…”\u003C\u002Fli>\u003Cli>Under the section, \u003Cstrong>“Diabetes Management”\u003C\u002Fstrong>\u003Cbr>o “Bilberry extract has shown promise in helping regulate blood sugar levels, making it a potential ally for individuals with diabetes or those at risk of developing the condition…”\u003C\u002Fli>\u003Cli>Under the section, \u003Cstrong>“Anti- Inflammatory Properties”\u003C\u002Fstrong>\u003Cbr>o “Chronic inflammation is linked to a wide range of health issues, from arthritis to cancer. Bilberry's anti-inflammatory properties, may help alleviate inflammation and reduce the risk of chronic diseases associated with prolonged inflammation.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>“Antioxidants and Aging: The Key to a Youthful Glow and Enhance Health”\u003C\u002Fstrong> https:\u002F\u002Foptihealthproducts.com\u002Fblogs\u002Fnews\u002Fantioxidants-and-aging-the-key-to-a-youthful-glow-and-enhanced-health\u003C\u002Fp>\u003Cul>\u003Cli>Under the section, \u003Cstrong>“Cognitive Function”\u003C\u002Fstrong>\u003Cbr>o “Antioxidants can help reduce oxidative damage in brain cells, potentially lowering the risk of age-related cognitive decline and diseases like Alzheimer's.”\u003C\u002Fli>\u003Cli>Under the section, \u003Cstrong>“Cardiovascular Health”\u003C\u002Fstrong>\u003Cbr>o “Antioxidants like flavonoids and vitamin E can improve heart health by reducing oxidation of cholesterol, lowering blood pressure, and improving arterial flexibility. This can decrease the risk of cardiovascular diseases, which are a major health concern for aging populations.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>This post links to the following blog on the firm’s website “Seeing Clearly: Combating Oxidative Stress and Macular Degeneration – OptiHealth Products”\u003Cbr>o “[A]s we age, the risk of vision-related conditions such as macular degeneration becomes increasingly prevalent. Central to this degenerative process is oxidative stress, which wreaks havoc on the delicate structures of the eye. In this blog, we explore the intricate relationship between oxidative stress and macular degeneration, shedding light on how OPC antioxidants offer a beacon of hope in preserving vision and ocular health.”\u003C\u002Fp>\u003Cul>\u003Cli>Under the section \u003Cstrong>“Understanding Oxidative Stress and Macular Degeneration”\u003C\u002Fstrong>\u003Cbr>o “In the context of ocular health, oxidative stress plays a significant role in the development and progression of macular degeneration. The macula, a small but crucial part of the retina responsible for central vision, is particularly vulnerable to oxidative damage. Over time, this oxidative assault leads to the deterioration of macular tissues, resulting in blurred vision, distortion, and eventual vision loss—a condition known as age-related macular degeneration (AMD).”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>“The Neuroprotective Benefits of OPC Antioxidants” \u003C\u002Fstrong>https:\u002F\u002Foptihealthproducts.com\u002Fblogs\u002Fnews\u002Fthe-neuroprotective-benefits-of-opc-antioxidants\u003Cbr>o “\u003Cstrong>Supporting Cognitive Function\u003C\u002Fstrong>: Cognitive decline is a hallmark feature of aging and neurodegenerative diseases such as Alzheimer's and Parkinson's. OPC antioxidants offer a ray of hope by promoting cognitive function and memory retention, potentially slowing the progression of age-related cognitive decline.”\u003C\u002Fp>\u003Cp>Your product is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Your Super Antioxidant (OPCXtra) product is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, your Super Antioxidant (OPCXtra) product fails to bear adequate directions for its intended use, and therefore the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be addressed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplement@fda.hhs.gov. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria Knirk, JD, MBA\u003Cbr>Acting Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003Cstrong> Bilbery is an ingredient in the firm’s product “OPXtra” \u003C\u002Fstrong>https:\u002F\u002Foptihealthproducts.com\u002Fproducts\u002Fopcxtra-isotonic-opc-super-antioxidant-supplement\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nMr. Russell Dickson\n\nRecipient Title\n\nPresident\n\nOptiHealth Products, Inc.\n\n275 River Rd\n\nSaint James, NY 11780\n\nUnited States\n\nsupport@optihealthstore.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nApril 29, 2026\nWARNING LETTER\nCMS # 704899\nDear Mr. Dickson:\nThe U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Foptihealthproducts.com in December 2025 and has determined that you take orders there for your product Super Antioxidant (OPCXtra). We also reviewed your social media website at https:\u002F\u002Fwww.facebook.com\u002FOptiHealthProducts where you direct consumers to your website,\nhttps:\u002F\u002Foptihealthproducts.com\u002F to purchase your products. The claims on your website, https:\u002F\u002Foptihealthproducts.com\u002F establish that this product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\nExamples of some of the claims that provide evidence that your product is intended for use as a drug include:\n“6 Remarkable Benefits of Bilberry Extract1” https:\u002F\u002Foptihealthproducts.com\u002Fblogs\u002Fnews\u002F6-remarkable-benefits-of-bilberry-extract\nUnder the section, “Heart Health Support”\no “The antioxidants in bilberries are believed to help reduce the risk of heart disease by improving blood vessel function, reducing blood pressure, and lowering cholesterol levels…”\nUnder the section, “Diabetes Management”\no “Bilberry extract has shown promise in helping regulate blood sugar levels, making it a potential ally for individuals with diabetes or those at risk of developing the condition…”\nUnder the section, “Anti- Inflammatory Properties”\no “Chronic inflammation is linked to a wide range of health issues, from arthritis to cancer. Bilberry's anti-inflammatory properties, may help alleviate inflammation and reduce the risk of chronic diseases associated with prolonged inflammation.”\n“Antioxidants and Aging: The Key to a Youthful Glow and Enhance Health” https:\u002F\u002Foptihealthproducts.com\u002Fblogs\u002Fnews\u002Fantioxidants-and-aging-the-key-to-a-youthful-glow-and-enhanced-health\nUnder the section, “Cognitive Function”\no “Antioxidants can help reduce oxidative damage in brain cells, potentially lowering the risk of age-related cognitive decline and diseases like Alzheimer's.”\nUnder the section, “Cardiovascular Health”\no “Antioxidants like flavonoids and vitamin E can improve heart health by reducing oxidation of cholesterol, lowering blood pressure, and improving arterial flexibility. This can decrease the risk of cardiovascular diseases, which are a major health concern for aging populations.”\nThis post links to the following blog on the firm’s website “Seeing Clearly: Combating Oxidative Stress and Macular Degeneration – OptiHealth Products”\no “[A]s we age, the risk of vision-related conditions such as macular degeneration becomes increasingly prevalent. Central to this degenerative process is oxidative stress, which wreaks havoc on the delicate structures of the eye. In this blog, we explore the intricate relationship between oxidative stress and macular degeneration, shedding light on how OPC antioxidants offer a beacon of hope in preserving vision and ocular health.”\nUnder the section “Understanding Oxidative Stress and Macular Degeneration”\no “In the context of ocular health, oxidative stress plays a significant role in the development and progression of macular degeneration. The macula, a small but crucial part of the retina responsible for central vision, is particularly vulnerable to oxidative damage. Over time, this oxidative assault leads to the deterioration of macular tissues, resulting in blurred vision, distortion, and eventual vision loss—a condition known as age-related macular degeneration (AMD).”\n“The Neuroprotective Benefits of OPC Antioxidants” https:\u002F\u002Foptihealthproducts.com\u002Fblogs\u002Fnews\u002Fthe-neuroprotective-benefits-of-opc-antioxidants\no “Supporting Cognitive Function: Cognitive decline is a hallmark feature of aging and neurodegenerative diseases such as Alzheimer's and Parkinson's. OPC antioxidants offer a ray of hope by promoting cognitive function and memory retention, potentially slowing the progression of age-related cognitive decline.”\nYour product is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\nYour Super Antioxidant (OPCXtra) product is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, your Super Antioxidant (OPCXtra) product fails to bear adequate directions for its intended use, and therefore the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be addressed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplement@fda.hhs.gov. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMaria Knirk, JD, MBA\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program\n____________________\n1 Bilbery is an ingredient in the firm’s product “OPXtra” https:\u002F\u002Foptihealthproducts.com\u002Fproducts\u002Fopcxtra-isotonic-opc-super-antioxidant-supplement","OptiHealth Products, Inc.","optihealth-products-inc-704899-04292026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Foptihealth-products-inc-704899-04292026","2026-10-26T08:09:38.562979+00:00","2026-05-12","704899","Dietary Supplements","Mr. Russell Dickson","2026-08-19T04:43:05.134+00:00","2026-04-29",{"id":162,"raw":163,"subject":167,"body_html":168,"body_text":169,"firm_name":170,"letter_id":171,"created_at":152,"fei_number":19,"letter_url":172,"updated_at":173,"action_type":22,"case_status":23,"posted_date":174,"marcs_cms_no":175,"product_type":176,"closeout_date":19,"issuing_office":166,"recipient_name":177,"body_fetched_at":178,"delivery_method":179,"recipient_title":19,"reference_number":180,"action_taken_date":174,"medical_device_id":19,"response_letter_date":19},345,[164,164,165,166,167,13,13,13],"\u003Ctime datetime=\"2026-02-10T05:00:00Z\">02\u002F10\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprodx-health-720762-02102026\">ProDx Health\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-720762\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Andreas Kogelnik, MD, PhD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder &amp; Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>ProDx Health\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1190 O'Brien Dr\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Menlo Park\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94025\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@prodxhealth.com\"> support@prodxhealth.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 10, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 26-720762\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Dr. Andreas Kogelnik:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA or the Agency) has learned that your firm, ProDx Health, is offering for sale in the United States human immunodeficiency virus (HIV) serological diagnostic sample self-collection kits (hereinafter, your “sample self-collection kits”) without marketing authorization, in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act).\u003Ca id=\"footnoteref1_ygaot82\" href=\"#footnote1_ygaot82\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp; &nbsp;Under section 201(h)(1) of the FD&amp;C Act, 21 U.S.C. 321(h)(1), your sample self-collection kits are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>FDA has reviewed your company’s website at https:\u002F\u002Fprodxhealth.com (last visited February 2026) and your firm’s February 3, 2026 response to previous FDA correspondence. &nbsp;Based on our review of these materials, your firm offers its sample self-collection kits for delivery to individuals and intends for these individuals to use the kits to self-collect serological samples and ship those samples to laboratories for HIV testing. FDA has determined that your sample self-collection kits are adulterated under section 501(f)(1)(B) of the FD&amp;C Act, 21 U.S.C. 351(f)(1)(B) because they do not have an approved premarket approval application (PMA) in effect pursuant to section 515(a) of the FD&amp;C Act, 21 U.S.C. 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the FD&amp;C Act, 21 U.S.C. 360j(g). &nbsp;Your sample self-collection kits are also misbranded under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o), because notification of the intent to introduce the device into commercial distribution has not been provided to the Agency, as required by section 510(k) of the FD&amp;C Act, 21 U.S.C. 360(k). &nbsp;\u003C\u002Fp>\u003Cp>FDA has not authorized your firm’s sample self-collection kits for use in HIV serological diagnostic testing. Notably, this letter focuses on your sample self-collection kits and is not intended to be a comprehensive list of potential issues with your firm’s products.\u003C\u002Fp>\u003Cp>Without appropriate testing, data review, and marketing authorization, there is a lack of assurance of the safety and effectiveness of your sample self-collection kits. Self-collection raises several issues of importance, including, for example, whether the user can safely and properly collect the specimen, if the sample has been properly shipped, and if there is adequate stability of the specimen given the time lapse between collection and testing and the potential impact of shipping conditions. We note that there are FDA-approved over-the-counter HIV self-tests that can help meet the needs of individuals who wish to test themselves at home or who are unable to access other testing options.\u003C\u002Fp>\u003Cp>The violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. FDA requests that your firm immediately cease any activities that result in the misbranding or adulteration of your sample self-collection kits. Your firm should take prompt action to address the violations identified in this letter. &nbsp;Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. &nbsp;If you believe that your firm’s sample self-collection kits are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration in your response to this letter.\u003C\u002Fp>\u003Cp>Within fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. &nbsp;Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002Fs\u002F\u003Cbr>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_ygaot82\">\u003Ca href=\"#footnoteref1_ygaot82\">1\u003C\u002Fa>The letter FDA issued you on January 8, 2026, erroneously referred to your device as a “dried blood\nspot (DBS) card” self-collection kit. We have removed that letter from our website and are issuing this\namended Warning Letter.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 26-720762\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nAndreas Kogelnik, MD, PhD\n\nRecipient Title\n\nFounder & Chief Executive Officer\n\nProDx Health\n\n1190 O'Brien Dr\n\nMenlo Park, CA 94025\n\nUnited States\n\nsupport@prodxhealth.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nFebruary 10, 2026\nCBER 26-720762\nDear Dr. Andreas Kogelnik:\nThe United States Food and Drug Administration (FDA or the Agency) has learned that your firm, ProDx Health, is offering for sale in the United States human immunodeficiency virus (HIV) serological diagnostic sample self-collection kits (hereinafter, your “sample self-collection kits”) without marketing authorization, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act).1 Under section 201(h)(1) of the FD&C Act, 21 U.S.C. 321(h)(1), your sample self-collection kits are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nFDA has reviewed your company’s website at https:\u002F\u002Fprodxhealth.com (last visited February 2026) and your firm’s February 3, 2026 response to previous FDA correspondence. Based on our review of these materials, your firm offers its sample self-collection kits for delivery to individuals and intends for these individuals to use the kits to self-collect serological samples and ship those samples to laboratories for HIV testing. FDA has determined that your sample self-collection kits are adulterated under section 501(f)(1)(B) of the FD&C Act, 21 U.S.C. 351(f)(1)(B) because they do not have an approved premarket approval application (PMA) in effect pursuant to section 515(a) of the FD&C Act, 21 U.S.C. 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the FD&C Act, 21 U.S.C. 360j(g). Your sample self-collection kits are also misbranded under section 502(o) of the FD&C Act, 21 U.S.C. 352(o), because notification of the intent to introduce the device into commercial distribution has not been provided to the Agency, as required by section 510(k) of the FD&C Act, 21 U.S.C. 360(k).\nFDA has not authorized your firm’s sample self-collection kits for use in HIV serological diagnostic testing. Notably, this letter focuses on your sample self-collection kits and is not intended to be a comprehensive list of potential issues with your firm’s products.\nWithout appropriate testing, data review, and marketing authorization, there is a lack of assurance of the safety and effectiveness of your sample self-collection kits. Self-collection raises several issues of importance, including, for example, whether the user can safely and properly collect the specimen, if the sample has been properly shipped, and if there is adequate stability of the specimen given the time lapse between collection and testing and the potential impact of shipping conditions. We note that there are FDA-approved over-the-counter HIV self-tests that can help meet the needs of individuals who wish to test themselves at home or who are unable to access other testing options.\nThe violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. FDA requests that your firm immediately cease any activities that result in the misbranding or adulteration of your sample self-collection kits. Your firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your firm’s sample self-collection kits are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration in your response to this letter.\nWithin fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002Fs\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n\n1The letter FDA issued you on January 8, 2026, erroneously referred to your device as a “dried blood\nspot (DBS) card” self-collection kit. We have removed that letter from our website and are issuing this\namended Warning Letter.","ProDx Health","prodx-health-720762-02102026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprodx-health-720762-02102026","2026-10-26T08:09:44.671953+00:00","2026-02-10","720762","Biologics","Andreas Kogelnik, MD, PhD","2026-08-19T05:07:15.753+00:00","Via UPS and EMAIL","CBER 26-720762",8,{"510k":183,"classification":184,"enforcement":185,"event":186,"event_backfill":187,"pma":188,"warning_letter":189},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]